Did you know that your babys genetic makeup was determined at conception? From the moment the sperm met the egg, your little ones genetic code DNA began forming. Its made up of 23 pairs of chromosomes. Sometimes, though, extra chromosomes make their way into the mix and can result in something called a trisomy.

Edwards syndrome is also known as trisomy 18. It means a person has an extra copy of chromosome number 18, leading to issues with development. Heres more about the symptoms of this syndrome, what causes it, and what you might expect after a diagnosis.

Trisomy 18 is a rare genetic disorder that affects approximately 1 in every 3,315 births in the United States around 1,187 babies each year.

In typical development, a baby gets 23 pairs of chromosomes from its parents during conception 22 are called autosomes, and 1 set is made up of sex chromosomes (X and/or Y, depending on the babys sex).

The word trisomy means three bodies. When there are three copies of the chromosome versus the usual two, it creates an imbalance. As a result, a baby may be born with certain structural changes some of which may lead to miscarriage, stillbirth, or death after the baby is born.

Babies can be born with an extra copy of chromosome 18 in each cell in the body. This is called complete trisomy 18 and causes more serious health outcomes.

Mosaic trisomy 18 happens when only some cells in the body contain the extra chromosome. Around 5 percent of babies with trisomy 18 have the mosaic form. This generally leads to milder irregularities and longer life expectancy.

Partial trisomy 18 happens when an extra copy of chromosome 18 attaches to another chromosome. Again, the severity of the syndrome tends to be associated with the total number of cells affected by the trisomy. So, a partial trisomy tends to have less severe effects and longer life expectancy.

You may not notice anything different in your pregnancy if your baby has Edwards syndrome. In fact, you may not learn about your babys diagnosis until after your doctor orders certain prenatal screening tests, like:

Some families do not discover their childs diagnosis until birth, when the following physical features may include:

Other health issues may include:

Trisomy 18 is caused by any situation that leads to an extra copy of chromosome 18 in the body.

In most cases, it happens when the sperm meets the egg during conception. In one scenario, the reproductive material of either parent may spontaneously divide. In another, the trisomy may happen as cells divide after fertilization. Whatever the case, the extra chromosome happens at random.

Translocation is another possibility, which means that parts of chromosomes break off and attach to other chromosomes. This may happen randomly or through a balanced translocation, in which one parent has a set of chromosomes that arent typical but are balanced. When chromosomes are balanced, they dont cause medical issues. After reproduction, though, genetic information passed on may cause a trisomy.

Edwards syndrome may be diagnosed at some point during your pregnancy. You may have a cell-free DNA screening (cfDNA) at any time after 10 weeks of pregnancy and until delivery. cfDNA is a simple blood test that screens for genetic conditions. A positive result on this test means youll need further testing to confirm the results.

Other tests during pregnancy include:

Other times, trisomy 18 may not be diagnosed until after your baby is born. Your childs doctor may diagnose it based on:

There is no cure for trisomy 18. Since babies with this condition tend to have multiple health issues, youll work with a team of doctors to create a customized treatment plan. In more severe cases, some families favor palliative care or hospice care.

Treatments are more about making a child comfortable or correcting the issues that affect an individual child. For example, surgery may be an option to treat things like:

As a child grows, they may need support academically and physically. Early intervention and special education programs can help fill these gaps.

You may be surprised to learn that there are very few risk factors for Edwards syndrome.

There may be an increased chance of having a baby with a trisomy as you get older. While different reports show mothers in their late teens and 20s can have children with trisomy 18, the mean age is closer to 32.5 years old.

In rare cases, trisomy 18 may be inherited from a biological parent (through balanced translocation). If you already have had one child with a trisomy, your doctor may suggest getting genetic testing to assess your chances of having another child with a similar condition.

The vast majority of the time, though, Edwards syndrome happens by chance during conception when the sperm meets the egg.

Its important to be prepared for all possibilities with a condition like trisomy 18. Researchers share that nearly half of all babies born with Edwards syndrome who survive delivery may not live beyond the first week of life.

That said, the severity of the syndrome depends on the type (complete, mosaic, partial, etc.) and whatever effects it has on your individual child. All children are different, and all outlooks will be unique as a result.

Of children born with Edwards syndrome, nearly 50 percent will not survive beyond the first week of life. However, around 10 percent will reach their first birthday, and some may live to their teen years or even adulthood, but they will need medical support or therapies, including:

While you may be worried about your child and the outlook over the long term, try taking it day by day. And dont forget about yourself or your own mental health in the process.

There is support for families with children who have Edwards syndrome. Consider contacting the Trisomy 18 Foundation or the Support Organization for Trisomy 13, 18, and Related Disorders (SOFT). Your doctor may also be able to help connect you with a local group for support and other resources.

View original post here:
Trisomy 18: Diagnosis, Causes, Prognosis, and More - Healthline

Recommendation and review posted by Bethany Smith

After that, you sit back and you wait for your results to come in and you wait for information to come to you. So if there's a new survey that comes out, well let you know, and it's up to the individual, how much, or how little they want to participate. Again, we'd love everyone to continue to complete the surveys as they go along because the more information that we have about lifestyle, environment, family health history, social determinants of health, all of that helps researchers have a more dynamic and full understanding of what is going on. Not only with the individual, but they can see it on a larger scale in communities and different populations.

La Keisha Jones:One thing with a trial is that you are providing treatment. We do not provide treatment. We are just collecting information to create a data cohort of information for researchers to look at and that would be the difference there. The one thing that we do offer, though, is that if something is discovered individuals are notified. If there is something of health significance with the genetic results that is found, then a genetic counselor is offered to them to explain what this means to them and what it can mean to their family.

Our program is giving information back so that people can have more informed conversations. They can be more informed about their risk for a disease possibly, or the risks that they may or may not face. Again, if something comes back, it doesn't necessarily mean that disease could take place, but if they are aware of it, they can keep it to themselves or they could share it with their family, or they could take it to their doctor and just say, "Hey, you know, we would never have known this because genetic testing isn't on the list of things that normally take place and I might be at risk. What should we do about it?" Maybe it means earlier screenings. Maybe it means making healthier decisions.

There are also different levels of participation. Some people just decide they want to do the online portion. Some people want to provide genetic information but not to receive their results. You have the option to say yes, no, maybe, or I don't know yet.

Lakeisha Jones:Anyone over the age of 18 can enroll. It doesn't matter if you have any diseases or don't have any diseases, anything of that sort. We do ask individuals to have an address in the U.S. and contact information here in the U.S. for about six months out of the year, just so that when information is returned, they can make sure that they can be followed up with and be contacted. You don't need health insurance to participate and you do not need to be a U.S. citizen.

That's the beautiful thing about New York, too, we have a very diverse staff. Our staff is bilingual, English and Spanish.

To sign up online or find phone numbers of where to talk to someone about the program, you can visit the New York City Consortium websiteor call 212-205-9927.

Here is the original post:
The 'All of Us' Research Program Is Helping Make Medicine More Precise for Diverse Populations. Five Years In, How Is It Going? - Columbia | Neighbors

Recommendation and review posted by Bethany Smith

Familial cancer syndrome is a genetic condition that increases the risk of various cancers in related family members. Hereditary cancer disorders are caused by mutations in certain genes passed down from parents to offspring, and certain cancer patterns can be found in families with hereditary cancer syndrome.

This could be due to other causes like the fact that family members share certain activities or exposures that raise cancer risk, such as smoking. Rarely, factors that run in families, such as obesity, may also increase cancer risk.

The common cancers and associated syndromes:

Hereditary Breast and Ovarian Cancer (HBOC) syndrome: tumors are commonly found in women younger than the average age and are caused by a hereditary mutation in either the BRCA1 or BRCA2 gene.

Lynch syndrome: also known as hereditary non-polyposis colorectal cancer, is the most common genetic syndrome that raises a person's risk of colon cancer in those under the age of 50.

Li-Fraumeni syndrome: a rare genetic disease that causes a variety of malignancies in individuals in their twenties and thirties, including sarcoma, leukemia, brain tumors, adrenal cortex cancer, and breast cancer.

Genetic counseling and testing: People with a strong family history of cancer may be interested in learning more about their genetic composition. Since hereditary mutations impact all cells in a person's body, genetic testing on blood or saliva samples is frequently used to detect them.

Germline mutation

Any observable alteration within germ cells is referred to as a germline/germinal mutation. When a mutant sperm or oocyte combine to form a zygote, the only mutations that can be passed on to progeny are those in these cells.

Individuals with mutations in tumor suppressor genes or proto-oncogenes are more likely to develop tumors. About 5-10% of all cancers are inherited through defective inherited genetic alterations.

Because the protein produced inhibits tumors, those who inherit germline mutations in TP53 are prone to specific cancer types. Breast and ovarian cancer as well as hereditary non-polyposis colorectal cancer, are two further examples.

Indias stance on family cancer syndrome

According to the WHO and the American Cancer Society, cancer kills one out of every six people on the planet, more than HIV/AIDS, TB, and malaria combined.

Are these genetic tests available in India?

Yes, these genetic tests are now accessible in India and require only a simple blood test (Multi-gene panel testing).

Who must undergo these tests?

Strong family history of Cancers like Breast cancer, Ovarian cancer, Colon cancer etc. happening in multiple family members and or many generations needs to get tested.

When cancer happens at an early age say <30 years, needs to be tested again.

There are other situations where one needs to get tested for which they can consult their Oncologist or physician.

What preventive strategies are available?

Those who test positive for these syndromes have a few cancer prevention options like preventive surgeries, tablets, and also aggressive cancer screening programs to detect cancers at early stages and treat them effectively.

This data can help clinicians make better clinical management decisions. Furthermore, mutations in particular genes boost therapeutic response, contributing to precision/personalized medicine, in which patients are treated depending on their mutations.

Given the numerous benefits of detecting genetic differences in hereditary malignancies, the medical community has been working to make genetic testing more affordable and accessible to the general people, allowing for faster disease diagnosis, management, and treatment.

-The author Dr. Vivek Belathur is MD, DM, ECMO, Senior Consultant Medical Oncology at Fortis Hospitals, Bannerghatta Road. The views expressed are personal.

(Edited by : Priyanka Deshpande)

First Published:Apr 07, 2022, 08:42 PM IST

Read the original:
World Health Day | Family Cancer Syndrome: What genes tell us about the risk of developing cancer - CNBCTV18

Recommendation and review posted by Bethany Smith

DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples

AUSTIN, Texas, April 13, 2022 /PRNewswire/ --Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, todayannounced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, Prospera Heart, has been published in the Journal of Heart and Lung Transplantation - a leading journal with the highest impact factor in the transplantation sector2.

This multi-site clinical validation, named the DEDUCE study, was conducted in partnership with the University of Utah and the University of California, San Diego and evaluated 703 prospective and 108 retrospective samples, (811 samples total) from 223 patients. The patient cohort included a large number of biopsy-confirmed rejections - 32 samples correlating to antibody mediated rejection (AMR) and 17 samples correlating to acute cellular rejection (ACR). The Prospera Heart test exhibited excellent performance with an overall 0.86 AUC for identifying acute rejection. Notably, the performance was also exceptional in the prospective arm-alone (0.87 AUC3).

"There is a critical unmet need for an accurate and less invasive approach for rejection surveillance after heart transplant," said Josef Stehlik, senior author and medical director of the Heart Transplant Program and co-chief of the Advanced Heart Failure Program at the University of Utah School of Medicine. "Incorporation of a noninvasive assay to reduce or replace the use of endomyocardial biopsy requires a very high performance standard. The Prospera Heart test demonstrated performance that I believe the clinicians will be very excited about."

The study also included an analysis on the use of dd-cfDNA concentration alone to identify rejection. dd-cfDNA concentration demonstrated an AUC of 0.88 overall, and 0.89 in the prospective cohort, highlighting the potential (upon additional studies and evaluation) to further improve the performance of the Prospera Heart test by evaluating both dd-cfDNA concentration and donor fraction.

The Prospera Heart test was launched in late 2021 and will continue to be evaluated in a variety of additional studies, including the NIH-supported DTRT study, and the Natera-sponsored DETECT trial, expected to be the first randomized controlled trial comparing dd-cfDNA surveillance to endomyocardial biopsy surveillance in patients of all risk profiles from 30 days post transplant. Combined, these trials are expected to include more than 775 heart transplant patients across multiple centers, underscoring Natera's commitment to generating robust scientific evidence.

About the Prospera test

TheProsperatest leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. It has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit http://www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available atwww.natera.com/investorsandwww.sec.gov.

ContactsInvestor Relations:Mike Brophy, CFO, Natera, Inc., 510-826-2350Media:Kate Stabrawa, Communications, Natera, Inc., 720-318-4080[emailprotected]

References

SOURCE Natera, Inc.

Excerpt from:
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection - PR Newswire

Recommendation and review posted by Bethany Smith

Image: Professor John Yarnold (left), Professor Pascal Meier (middle) and Professor Clare Isacke.Credit:soora.co.uk

As research efforts become bigger and more ambitious, there is a real need to bring together researchers with diverse scientific backgrounds and perspectives to solve complex scientific problems. This type of multidisciplinary approach taken by The Breast Cancer Team at the ICR and The Royal Marsden NHS Foundation Trusthas been critical to their success in making transformational discoveries in breast cancer.

Twelve researchers from the ICR and The Royal Marsden Breast Cancer Team have been awarded the 2022 Team Science Award from the American Association for Cancer Research (AACR). The award recognises the significant contributions to the breast cancer research community made by the multidisciplinary team spanning a spectrum of discovery biology, molecular pathology, trial statistics and clinical science.

Here, we celebrate the teams tremendous achievements, which are underpinned by more than two decades of research.

In 1995, Professor Alan Ashworth, then at the ICR but now President of the UCSF Helen Diller Family Comprehensive Cancer Center, was part of a team of researchers that discovered the second breast cancer susceptibility gene, BRCA2. Building on this work, Professor Ashworth and Professor Andrew Tutt(then Ashworths MRC Clinical Training Fellow and PhD student), along with a wider group in the Ashworth lab, uncovered the important role of the BRCA2 gene in DNA damage repair revealing how it might be targeted with drugs such as carboplatin.

Together with Professor Chris Lordwho had joined the lab, and Professor Steve Jacksonsteam at the UK biotech company KuDOS, in 2005, they went on to identify the first synthetic lethal interaction between the BRCA1/2 genes and the DNA damage repairing enzyme Poly-ADP-Ribose Polymerase 1, or PARP1.

The concept of synthetic lethality is based on the dependency between a pair of cancer genes, where loss of function of either individual gene will allow the cancer cell to survive, but loss of function of both genes simultaneously will cause the cancer cell to die.

The collaboration with the KuDOS team, who had discovered a PARP inhibitor drug called olaparib, showed that blocking PARP1 caused cancer cells carrying BRCA1 or BRCA2 mutations to die. The striking results from the Ashworth lab stimulated Professor Tutt and the Ashworth group to design a Phase I clinical trial in 2008, together with ICR clinician scientist Professor Johann de Bonoand Professor Stan Kayeat The Royal Marsden, that focussed on BRCA1/2 mutation carriers.

Commenting on the discoveries, Professor Lord said, I think we knew from a very early stage that this was quite a significant finding. But at the time, we didnt fully realise that it would go all the way to actually getting approved and used worldwide. For us lab scientists and clinician scientists, these are things that we came into research to do. From an emotional perspective, it is incredibly rewarding and an enormous privilege to be able to contribute to things that actually make a difference to people.

The teams collaborative efforts pioneered the use of synthetic lethality as a new therapeutic strategy in cancer. This has had a particular impact in breast cancer, as well as in ovarian, prostate and pancreatic cancer, where PARP inhibitors are also now used.

Phase III trials with olaparib, that followed the phase II proof of concept studies led by Professor Tutt in 2010, resulted in the drugs approval in treating advanced BRCA1/2 mutated breast cancers. Olaparib was approved for breast cancer by regulators in the US, the Food and Drug Administration (FDA), in 2018, and in Europe, the European Medicines Agency (EMA), in 2019. The FDA and EMA have also approved the use of olaparib in ovarian, prostate and pancreatic cancers.

The development and approval of olaparib has transformed how advanced BRCA1/2 mutated breast cancers are treated worldwide. Olaparib is the first cancer treatment targeted against an inherited genetic fault. This breakthrough has had a huge impact on thousands of people with breast cancer, enabling patients to live longer and have a better quality of life while receiving treatment.

More recently, the results from the OlympiA trial, that was led by Professor Tutt as the Breast International Groups Global OlympiA Steering Committee Chair,revealed that adding olaparib to standard treatment for early-stage breast cancer in patients with inherited BRCA1/2 mutations can improve survival and reduce the risk of recurrence. The trial also supports testing for germline BRCA1/2 mutations, which has now been established as an important part of treatment selection in early breast cancer. The teams findings have impacted international treatment guidelines for both breast cancer therapy and genetic testing.

Professor Tutt said, This work brought together fundamental biologists, geneticists, biotech companies, early phase trials leaders and international collaborators at the phase III study stage. The award recognises the teamwork and amalgamation of skillsets required to change the way breast cancer is treated.

While the use of PARP inhibitors has been largely successful, not all patients who have inherited a faulty BRCA1 or BRCA2 gene respond to PARP inhibitors. Professors Lord and Tutt and their team are trying to understand how cancer cells become resistant to these drugs. They are uncovering ways to overcome resistance by identifying molecules that can be targeted using different drug combinations.

Developing smarter, kinder treatments for patients is a continuous cycle from the lab to the clinic and back again. Professor Lord said, Our collaboration with The Royal Marsden allows us to be a truly translational research centre. We can do biological research that informs new drug discovery projects and design of clinical trials, but we can also take observations from the clinic and feed them back into the lab where they can be dissected at a molecular level. This provides useful insight that can help to make new discoveries to overcome drug resistance.

Our researchers regularly present their latest findings at the AACR Annual Meeting in the US.

Find our more about the AACR conference

Oestrogen receptor positive, or ER+, breast cancer is the most common form of the disease it makes up about 80 per cent of cases and this is where the joint team made another major contribution recognised by the award. These cancers rely on oestrogen for their growth and can be treated using aromatase inhibitors that block the effects of the hormone.

The ICR and The Royal Marsden played a key role in the clinical development of aromatase inhibitors assessing their effectiveness over the years. The teams work in this field has been critical to understanding the biology of ER+ breast cancers and improving our knowledge of how these cancers become resistant to conventional hormone treatment.

Early trials involving Professor Mitch Dowsettfound that aromatase inhibitors were better than tamoxifen another type of hormone therapy for breast cancer at preventing the recurrence of ER+ breast cancers.

A seminal trial co-led by Professor Judith Bliss, an expert trial statistician and methodologist, demonstrated improved relapse-free survival in patients that switched to the aromatase inhibitor exemestane after two to three years of tamoxifen treatment compared with tamoxifen alone for five years. This trial played an instrumental role in changing practice guidelines for use of aromatase inhibitors in the clinic.

Professor Stephen Johnston, a consultant oncologist at The Royal Marsden, led the large-scale international MonarchE trialwhich aimed to identify new treatments that overcome resistance in ER+ breast cancer. The results showed that adding the drug abemaciclib a CDK4/6 inhibitor that prevents cell growth to hormone treatment significantly reduced the risk of the disease coming back in high-risk patients with early breast cancers.

The MonarchE trial was based on many years of research done at the ICR and The Royal Marsden and was a collaboration between both organisations, Eli Lilly and numerous international investigators. Abemaciclib was approved for adjuvant therapy by the FDA in the US in 2021 and just this month by the EMA.

Professor Bliss said, The ICR and The Royal Marsden bring together discovery science, clinical expertise and dedicated cancer specific trials methodology, which is ideal for designing scientifically robust, efficient and practice-changing clinical trials.

Professor Dowsett and his team also discovered an important biomarker Ki67, which marks newly divided cancer cells to evaluate the effectiveness of aromatase inhibitors in patients. The biomarker was subsequently developed into a test that is used to identify patients who might particularly benefit from hormone therapy.

The POETIC trialinvolved Professor Dowsett, Professor Bliss and Professor Ian Smith, and enrolled postmenopausal women who were planned to receive an aromatase inhibitor for five years following surgery. By starting the aromatase inhibitor two weeks before surgery and looking at how the Ki67 biomarker changed in patients tumours following the short-term therapy, the researchers were able to distinguish groups of patients with different risks of their cancer coming back.

Some patients started with a low level of the biomarker which stayed low after two weeks of treatment. The patients in this group had a very low chance of their cancer coming back during the next five years, with many of these patients able to be treated with aromatase inhibitor therapy alone. A minority of these patients were likely to still require chemotherapy if they exhibited certain high-risk features in their cancer.

For patients who had higher levels of the biomarker before treatment, assessing the levels again after two weeks of therapy showed that biomarker changes during that period affected the patients long-term outcome. Many of these patients had tumours that exhibited low levels of the biomarker following treatment. Patients whose biomarker levels stayed high following the brief exposure to aromatase inhibitors had the highest risk of their cancer coming back.

These findings helped to identify high-risk patients whose cancer was likely to come back and so required additional treatment above the current standard of care. This national trial engaged patients and doctors throughout the UK and helped to promote the desire for Ki67 biomarker testing as part of routine practice in the clinic.

Professor Johnston said, The pioneering work done by The Royal Marsden and the ICR is unrivalled elsewhere. Our close collaborations with the Cancer Research UK-funded Clinical Trials and Statistics Unitat the ICR and the scientists involved in the development of biomarkers made it possible to do the POETIC trial and plan the follow up POETIC-A trial, which started in 2020. These trials help to increase our understanding of the disease and how we can overcome resistance.

A measure of cancer treatment is not only how effective it is, but also how well tolerated it is by patients. Its important that research is used to find smarter and kinder treatments, and the joint team has excelled in this area.

The award recognises approaches that have led to de-escalation of breast cancer treatment. Long-standing research conducted by Professor John Yarnoldand Professor Bliss, and their wider teams, has revolutionised the way radiotherapy is delivered to people with breast cancer. This work was done in partnership with many other clinical leads at hospitals across the UK.

The findings from their clinical trials demonstrated that patients could be treated safely and effectively with fewer and bigger radiotherapy doses. Their remarkable discovery changed the treatment, for some patients, from being delivered in 25 doses over five weeks to just five doses over one week, reducing overall treatment time, the burden of that time on patients and hospital costs. This was particularly impactful during the Covid-19 pandemic when patients needed to receive treatment but minimise the time spent in hospitals.

Professor Bliss spoke about the impact of the radiotherapy trials saying, These trials investigated the balance of being able to keep recurrence rates down without causing more side effects. Our findings have been practice-changing and have had a great impact on the treatment pathways for breast cancer patients worldwide. They have also reduced inequalities by expanding access to the best treatment for patients in an impartial manner.

The team have also developed a test, known as a liquid biopsy, that detects tumour DNA circulating in the blood. By analysing samples of blood plasma from breast cancer patients to see if that tumour DNA is present, researchers can predict which patients are at risk of recurrence. This work, led by Professor Nick Turner, provides a less invasive way to assess patients and their response to therapy, avoiding the need for repeat tumour biopsies.

A recent phase II trial (plasmaMATCH), involving Professor Turner, Professor Bliss and Dr Alistair Ring, assessed the feasibility and clinical use of liquid biopsies in breast cancer patients it has shown promising results. The team have launched additional trials to further assess the potential use of liquid biopsies in guiding cancer therapy.

While most people with primary breast cancer, which hasnt spread, have a high survival rate because of the availability of effective treatments and the accessibility of tumours for surgical intervention, metastatic disease is still considered incurable.

Progress in treating advanced disease is urgently needed and the award recognised the discovery of molecular changes in breast cancer that drive some of the more aggressive behaviours in advanced breast cancer.

Professor Clare Isacke and her teams research focuses on how breast cancer cells interact with their environment during the early stages of metastatic colonisation. They have developed new ways to study advanced breast cancer using metastasis models in mice, which has provided important insights into how breast cancer cells adapt to survive in secondary sites and evolve to resist treatment. Their discoveries about how certain cells, called cancer associated fibroblasts, nourish tumour seedlings, have revealed potential therapeutic targets for advanced breast cancer.

Professor Pascal Meierand his team, whose work centres on cell death, have discovered proteins that regulate cell survival and inflammation. They are trying to change the way cancer cells die so that it activates the immune system and helps to fight the tumour cells more effectively. Their work uncovering how breast cancer cells escape death may help to develop new strategies for cancer therapies.

Image: Picture of the winning team from the ICR and The Royal Marsden. Credit:soora.co.uk

The ICR and The Royal Marsden have a close partnership that goes back many decades, which has been particularly productive for breast cancer research. Professor Johnston said, We are a close-knit team and have worked together for over 20 years. The regular dialogue between the basic scientists who are studying the biology of the disease and clinician scientists who are translating that into better treatments for patients facilitates easy transfer of knowledge. Our collaboration advances our understanding of breast cancer and also enables clinical trials to be set up relatively seamlessly.

Professor Lord also emphasised the unique partnership between the two organisations saying, Our close collaboration means any potential opportunity to translate is not lost. This ultimately means we can get new cancer treatments out to patients quickly.

Breast Cancer Now and Cancer Research UKfunded much of the teams research at the ICR. Professor Isacke said: The partnership between the ICR and The Royal Marsden really provides the best environment to do cancer research. Its a huge credit to the Breast Cancer Now charity, which set up a dedicated research centreat the ICR and created the space for us to do our research. They have continued to fund our research and support us all these years.

Speaking about the Team Science Award, Professor Tutt said, Its an amazing honour to receive this award. The AACR is one of the worlds biggest and most prestigious cancer research organisations and for them to have recognised a UK based team for the work weve done in breast cancer is a massive achievement.

Its unusual for this to be awarded to a team outside of the US. For us to have been that team, in fact for the second time now for the ICR, is a testament to what the ICR and its clinical partners at the Royal Marsden can achieve. We want to make fundamental discoveries that improve the outlook for our patients with breast cancer, and to be recognised for that, I think is as good as it gets.

He stressed, Each named member is a figurehead for a wider team who have been involved in the work, so this victory is shared by many.

Professor Lord agreed, It really does take an entire army of people to deliver all of that work. The AACR Team Science Award neatly illustrates that if you want to achieve things that make a real difference to people who actually have cancer, it needs a multidisciplinary team and involves an enormous amount of teamwork.

The winners of the AACR Team Science Award are Professor Alan Ashworth, Professor Judith Bliss, Professor Mitch Dowsett, Professor Clare Isacke, Professor Stephen Johnston, Professor Chris Lord, Professor Pascal Meier, Dr Alistair Ring, Professor Ian Smith, Professor Nick Turner, Professor Andrew Tutt, and Professor John Yarnold.

Here is the original post:
From bench to bedside and beyond: the team of scientists that transformed breast cancer treatment - The Institute of Cancer Research

Recommendation and review posted by Bethany Smith

Authorities said an arsonist likely burned down Knoxville's Planned Parenthood clinic on New Year's Eve in Dec. 2021.

KNOXVILLE, Tenn. It has been around 4 months since a Planned Parenthood medical clinic in East Knoxville was likely set on fire by an arsonist, according to the Knoxville Fire Department. It burned down on the morning of New Year's Eve in December 2021.

Leaders of the Planned Parenthood of Tennessee and North Mississippi branch said they planned to rebuild the clinic and welcome patients once again.

We will rebuild at our Cherry Street location," said Aimee Lewis, the vice president of external affairs. "We expect the design phase, which we are currently in, to take approximately 6 months and construction to take a year. While we work with our architects, builders and insurance to make this happen, we are exploring options to provide in-person services in some capacity in the meantime."

She said they are continuing to offer limited telehealth options and referrals for patients while trying to expand healthcare options by hiring more providers and staff.

In 2021, the clinic served almost 4,000 patients. More than 2,400 went to the medical facility for birth control and to test for sexually-transmitted diseases, while another 712 sought gender-affirming hormone therapy. Officials said 815 were there for abortion treatments.

The clinic had posted before burning down that it was closed for renovation "to enhance and expand our patient services."

Officials previously said they expected it would cost around $2.2 million to rebuild, in addition to the $2.2 million they had already spent on the renovation project the center burned down.

Recently, MacKenzie Scott donated a historic $275 million to support Planned Parenthood at the national level.

Regarding MacKenzie Scotts incredible generosity, Planned Parenthood of Tennessee and North Mississippi did not receive a donation," said Lewis. "However, this gift is a testament to the very strong health care network that the Planned Parenthood federation and its affiliates provide for its patients all over the country. Were excited to see what Ms. Scotts investment in our sister affiliates will do to bring care and education to the patients they serve.

Anyone with information about the arsonist or arsonists involved in the Knoxville branch's fire should reach out to KFD at 1-800-762-3017 or email them at KFDArson@Knoxvilletn.gov. They previously offered a reward of up to $10,000 for information.

More here:
'We will rebuild' | Knoxville Planned Parenthood leader expects year-and-a-half of work to reopen clinic - WBIR.com

Recommendation and review posted by Bethany Smith

CULTURAL INDOCTRINATION WAR.Recently, leftist activists and their allies in the media had a big success labeling a bill passed by the Florida Legislature as the "Don't Say Gay" bill. They claimed, without evidence, that the Republican-sponsored bill would ban the mention of homosexuality in Florida schools. In fact, the bill, now signed into law by Gov. Ron DeSantis, prohibited "classroom instruction" on "sexual orientation or gender identity" by teachers or other adults in kindergarten through third grade. It also said such instruction after third grade must be "age-appropriate" or "developmentally appropriate." In other words, it specifically allowed classroom instruction on such matters after third grade. Nevertheless, LGBTQIA+ activists called the bill "Don't Say Gay." Many media outlets and commentators picked it up immediately.

Now, just a month later, the same alliance is at it again. The Alabama Legislature has passed a bill banning hormone treatment, puberty blockers, and surgery for minors who say they want to change their gender. "Minors, and often their parents, are unable to comprehend and fully appreciate the risk and life implications, including permanent sterility, that result from the use of puberty blockers, cross-sex hormones, and surgical procedures," the Republican-sponsored bill says. "For these reasons, the decision to pursue a course of hormonal and surgical interventions to address a discordance between the individual's sex and sense of identity should not be presented to or determined for minors who are incapable of comprehending the negative implications and life-course difficulties attending to these interventions." A "minor," for the purposes of this measure, is defined in Alabama law as "a person who is under 19 years of age."

So the law bans certain drastic treatments and procedures for children 18 and under. And this is the headline of the New York Times story reporting it: "Alabama Lawmakers Approve Ban on Medical Care for Transgender Youth."

Subscribe today to the Washington Examiner magazine that will keep you up to date with what's going on in Washington. SUBSCRIBE NOW: Just $1.00 an issue!

A ban on medical care? If a "transgender youth," that is, 18 or under, breaks his or her leg or catches pneumonia or is diagnosed with cancer is that person denied medical care under the new law? Would it be illegal for a doctor to treat them? Obviously not. And is there a consensus that puberty blockers, hormone treatments, amputations, and other surgeries, irreversible actions, are appropriate "medical care" for young people age 18 and under? Those are questions raised by the New York Times headline.

NPR took a slightly different route, headlining its story "Alabama Legislature votes to ban gender-affirming medical care for transgender youth." The phrase "gender-affirming" has entered wide use quite recently and is a euphemism for medical procedures not to affirm but to change one's gender. For example, this explainer from the Mayo Clinic mentions "gender affirming genital surgical procedures, such as penile inversion vaginoplasty." For its part, the New York Times article describes the Alabama law as the criminalization of "gender-affirming surgeries."

The Biden White House is fully on board. On Thursday, press secretary Jen Psaki said, "To be clear, every major medical association agrees that gender-affirming healthcare for transgender kids is a best practice and potentially lifesaving." The Alabama law, Psaki continued, "would target trans youth with tactics that threaten to put pediatricians in prison if they provide medically necessary, lifesaving healthcare."

On March 31, the Biden administration released a statement celebrating what is called the "Transgender Day of Visibility." The statement used the word "affirm" or "affirming" 29 times. Some examples: The administration pledged to strengthen federal measures to "protect transgender youth against discrimination, including when those youth seek gender-affirming care." It pledged to emphasize "the positive impact of gender-affirming care on youth mental health." It pledged to confirm that "providing gender-affirming care is neither child maltreatment nor malpractice." It pledged to create an information bank to show why "gender-affirming care ... is important to transgender, nonbinary, and other gender expansive young people's well-being." It pledged to use the Justice Department to knock down laws like Alabama's by "reaffirming that transgender children have the right to access gender-affirming health care."

And so on. You get the idea. Not surprisingly, the phrase "gender-affirming" and its variants are showing up more and more in the media discussion of puberty blockers, hormone treatments, and surgery. Such measures are also benignly described as "medical care." And who could be against medical care? Who could respond negatively to a positive word like "affirming?"

Just like the "Don't Say Gay" situation, supporters of the Florida bill and now the Alabama bill, and other bills like them around the country, face a battle of language as well as substance. And with the current administration, the activist world, and much of the media arrayed against them, it is an uphill battle.

For a deeper dive into many of the topics covered in the Daily Memo, please listen to my podcast, The Byron York Show available on the Ricochet Audio Network and everywhere else podcasts can be found. You can use this link to subscribe.

See the original post here:
Cultural indoctrination war - Washington Examiner

Recommendation and review posted by Bethany Smith

Amryt Pharma plc

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Acromegaly patients were exposed to Mycapssa during the OPTIMAL Phase 3 Trial, including its open label extension (OLE), for a maximum treatment duration of 3.2 years

Study demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders - insulin-like growth factor 1 (IGF-1) within normal limits - maintained their long-term biochemical response at the end of the study

IGF-1 levels were stably maintained within normal limits at the end of the OLE period (mean IGF-1 levels at baseline and at the end of the OLE were 0.92 and 0.84 respectively)

Growth hormone (GH) levels also improved at the end of the OLE period (mean GH levels at baseline and at the end of the OLE were 0.79 and 0.45 respectively)

Long-term safety profile of Mycapssa during the OLE was consistent with that observed in prior studies

DUBLIN, Ireland, and Boston MA, April 13, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today presents long-term safety and efficacy data from the 2nd year open-label extension (OLE) of its global Phase 3 OPTIMAL clinical trial that compared Mycapssa (octreotide capsules) to placebo for maintenance of biochemical response in patients with acromegaly. The OPTIMAL trial supported the approval of Mycapssa in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

Susan L Samson, MD, PhD, at Mayo Clinic (Jacksonville, Florida), and lead investigator of the OPTIMAL study commented: These data together with the recently published positive results from the 3 years OLE period of the MPOWERED Phase 3 study further supports the long-term safety and efficacy of Mycapssa (oral octreotide) in acromegaly patients who were previously biochemically controlled on monthly injectable Somatostatin Receptor Ligands (iSRLs). The data showing that 100% of responders (IGF-1 within normal limits) maintained their response at the end of the 2nd year of the OLE, confirming the durability of response over time.

Story continues

Dr. Mark Sumeray, Chief Medical Officer of Amryt, commented: The OPTIMAL 2nd year OLE data show that acromegaly patients who were switched from iSRLs to Mycapssa may benefit from a daily oral treatment based on maintenance of long-term biochemical response.

OPTIMAL Phase 3 Trial Open-Label Long-Term Safety & Efficacy Data40 patients that completed the 9 months double-blind placebo controlled (DPC) core treatment phase elected to continue treatment with Mycapssa in the OPTIMAL open label extension study (20 patients that were originally randomized to Mycapssa and 20 that were randomized to placebo). Results from the first year were published previously and demonstrated that all patients who responded to Mycapssa (IGF-1 within normal limits) during the DPC period and enrolled in the OLE (n=14) completed the 48-week period and 93% (13/14) maintained their IGF-1 response within the normal limit at the end of this period. 32 patients continued treatment into the 2nd year of the OLE (18 of those originally randomized to Mycapssa during the DPC and 14 of those randomized to placebo).

Key 2nd year study outcomes included:

31 out of 32 patients (97%) of those enrolled to the 2nd year of the OLE completed 96 weeks in the OLE period

100% of evaluable patients, who entered the 2nd year OLE phase of the study as responders (IGF-1 within normal limits; N=17), maintained their long-term biochemical response at the end of the study. The average IGF-1 levels of enrolled patients were stably maintained within the normal limits at the end of the OLE period (mean IGF-1 levels at baseline OLE and at the end of the OLE were 0.92 and 0.84 respectively).

93% of all patients who entered the 2nd year OLE phase (N=32) were responders at the end of the 96 weeks OLE

The average GH levels of enrolled patients improved at the end of the OLE period (mean GH levels at baseline OLE and at the end of the OLE were 0.79 and 0.45 respectively)

Acromegaly patients were exposed to Mycapssa during the OPTIMAL study (including its OLE phase), for a median treatment duration of 2.1 years and a maximal exposure of 3.2 years

Patients in the OLE demonstrated a median compliance rate of 98% over this period of time

The long-term safety profile of Mycapssa during the OLE, was consistent with the safety profile observed during previous studies with Mycapssa with no new safety signals with long-term exposure

About the OPTIMAL Phase 3 TrialThe OPTIMAL trial (NCT03252353) was a randomized, double-blind, placebo-controlled, nine-month Phase 3 clinical trial of octreotide capsules in 56 adult acromegaly patients whose disease was biochemically controlled by injectable somatostatin analogs (octreotide or lanreotide). Patients were randomized on a 1:1 basis, to octreotide capsules or placebo. The primary endpoint of the trial was the proportion of patients who maintained their biochemical response (IGF-1 levels 1.0 ULN), at the end of the nine-month, double-blind, placebo-controlled period. Hierarchical secondary endpoints included: (i) proportion of patients who maintain GH response at 9 months; (ii) time to loss of response; and (iii) proportion of patients requiring reversion to prior treatment. The OPTIMAL study met the primary endpoint and all secondary endpoints which led to the US approval of Mycapssa, the first oral somatostatin analog, for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

FDA APPROVED INDICATION AND USAGEMycapssa delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONSMycapssa can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

The full US Prescribing Information for Mycapssa is available at http://www.mycapssa.com.

About AcromegalyAcromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease. Amryt estimates that approximately 8,000 adult acromegaly patients are chronically treated with somatostatin analog injections in the United States.

About Amryt Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryts commercial business comprises three orphan disease products metreleptin (Myalept/ Myalepta); oral octreotide (Mycapssa); and lomitapide (Juxtapid/ Lojuxta).

Myalept/Myalepta (metreleptin) is approved in the US (under the trade name Myalept) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this link.

Mycapssa (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa is the first and only oral somatostatin analog approved by the FDA. Mycapssa has also been submitted to the EMA and is not yet approved in Europe. For additional information, please follow this link.

Juxtapid/Lojuxta (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid) and in the EU, Israel, Saudi Arabia and Brazil (under the trade name Lojuxta). For additional information, please follow this link.

Amryt's lead development candidate, Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Filsuvez has been selected as the brand name for Oleogel-S10. The product does not currently have regulatory approval to treat EB.

Amryts pre-clinical gene therapy candidate, AP103, offers a potential treatment for patients with Dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders.

Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE) technology platform. For more information on Amryt, including products, please visit http://www.amrytpharma.com.

Forward-Looking StatementsThis announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

ContactsJoe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.comTim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com

See the original post here:
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in...

Recommendation and review posted by Bethany Smith

Your elevated hematocrit/hemoglobin might well be directly related to your TRT. If so, there are ways to address that. However, your TRT might only be partly to blame as there are other conditions that can either contribute to high hematocrit/hemoglobin or even give false readings.

Depending on your situation, here are several ways to address high levels of hematocrit/hemoglobin:

This is the most obvious solution to elevated hematocrit, but it's probably also the least popular. Hardly any man wants to use less testosterone and give up any of the increased energy, sexuality, and muscularity that the hormone has gifted him. But truth be told, a lot of men are probably taking more than they need. The standard TRT clinic dosage is 200 mg. a week, which is, frankly, equivalent to a mild steroid cycle.

A study conducted by the Department of Urology at University of California found that subcutaneous (subQ) injections (under the skin rather than into the muscle) led to higher levels of free T, along with evidence of subQ being physiologically superior to IM shots in several other important ways.

Men who received subQ injections of testosterone exhibited the following:

The second result is the kicker. Since subQ injections led to a 41% reduction in hematocrit levels, you could theoretically use the same dosage you use for intramuscular injections. Of course, given that subQ injections led to a 14% increase in total T, you might just use a lesser dosage anyhow and further reduce hematocrit while retaining all the positive effects of your TRT.

Studies have shown that testosterone creams and gels raise hematocrit less than intramuscular testosterone injections.

This is the standard go-to treatment for high hematocrit. Every pint donated has been shown to decrease hematocrit by about 3 points. Unfortunately, you'd likely have to continue to periodically donate blood if you hadn't adopted any other hematocrit-lowering strategies.

That being said, there's some evidence that hematocrit levels stabilize after donating blood five times. Whether that's universally true is unlikely.

You can donate blood to places like the Red Cross or have your doctor perform what's known as a "therapeutic blood draw." Be careful not to donate too often, though. Giving a pint of blood more than every two and a half months or so may lead to long stints of fatigue.

High hematocrit readings sometimes occur because the patient was simply dehydrated, making it appear that the concentration of red blood cells was higher than it really was.

Of course, one simple way to determine whether your high hematocrit was caused by dehydration is to do a little simple math: hematocrit must always be three times the value of hemoglobin. If it's lower (Hct<3 x Hb), you're over-hydrated. If it's higher (Hct>3 x Hb), you're dehydrated. Either way, you're getting a false value because of your hydration status.

Red meats are high in heme iron (the type of iron found only in animal tissues), which is more efficiently absorbed than non-heme iron (the type found in whole grains, nuts, seeds, legumes, and leafy greens), and ingesting it can raise hemoglobin and, subsequently, hematocrit.

Sleep apnea is a medical condition where patients suffer from fragmented sleep. They literally stop breathing from 10 to 50 seconds multiple times throughout the night.

As a result of this interrupted breathing/sleep, patients experience poor oxygen saturation, which forces the body to produce more red blood cells and more hemoglobin.

Evidence suggests that curcumin binds to ferric acid in the digestive system, thus reducing hemoglobin levels. Be sure to use micellar curcumin which is 95 times more bioavailable than regular curcumin with piperine.

If you've got high hematocrit/hemoglobin AND have high blood pressure, ask your doctor to consider switching your high blood pressure medicine to Losartan. It's been used by physicians since the early 2000s to bring down hematocrit in kidney transplant patients and patients with chronic obstructive pulmonary disease (COPD).

See original here:
TRT Side Effects: The Big One to Avoid - T NATION

Recommendation and review posted by Bethany Smith

Imagine your 13-year-old daughter is depressed and withdrawn and then, one day, she tells you shes trans and will, henceforth, be known as Sean. You must no longer call her by her dead name. Even the most liberal parent may swallow hard and ask her (them) to have counselling with an experienced psychologist who can explore those feelings before the teenager embarks on drastic hormone treatment.

Thats a loving reaction, in my book. Astonishingly, in some countries it would be illegal. Therapists are forbidden to try and find out if anything else may lie behind a young persons misery in their own body. According to trans activists, talking therapies are the same as conversion therapy, an abhorrent practice which puts pressure on a gay boy or girl to renounce their sexuality.

Stonewall, the LGBTQ campaign group, insists that only affirmation is acceptable. You are not allowed to suggest your child is confused or to point out that there has been an extraordinary increase in girls seeking to transition from female to male or that many of those girls have autism. Nor that some kids who think they are trans have been bullied for being gay.

I agree with Debbie Hayton, a transwoman and campaigner, who says that the denial of meaningful therapy for vulnerable youngsters is chilling. But loving parents who make the same objection are branded transphobic.

This is the background to the Governments U-turn in which it excluded trans people from legislation banning conversion therapy. The Prime Minister drew a crucial distinction, saying, There are complexities and sensitivities when you move from the area of sexuality to the question of gender ... I dont think its reasonable for kids to take decisions about their gender without a parents involvement.

Boris is right. It isnt reasonable and nor is it kind. Kids who are in a distressed state can fixate on one solution to all their problems. Society owes them more than a reckless rush down the clinic for hormones which will wreck their fertility.

How tragic that this personal matter should become a political football. Terrified of their ideological commissars, Labour MPs look like complete wallies as they refuse to confirm or deny whether a person with a penis can be a woman. Angela Rayners tortuous answer to that vexed question sounded like a stoned sociology lecturer speaking Swahili. Its encouraging to see women across the spectrum, from Mumsnet to radical feminists, uniting against this insulting nonsense.

Ironically, many trans people do not want all this aggro on their behalf. Its frightening. A wise friend of mine whose partner transitioned successfully says, Every family starts from a position of denial and sadness. Sometimes they are right, sometimes they are wrong. Exactly. Some children will turn out to be correct in believing they would feel more themselves as another gender. For others, gender dysphoria may have been a peg on which to hang all the neuroses which are so common in that difficult phase of life.

Those young people all deserve loving support and proper counselling. What they dont need is fearful affirmation as they make the biggest, potentially most irreversible, decision of their lives.

Much amusement here at Pearson Towers after a headache and feeling tired were added to the official list of Covid symptoms. Isnt that the chronic and irreversible condition called Being Over 50?

Before half the population decided to throw a Covid sickie (Cickie?), Sajid Javid said that he personally would first reach for the Nurofen and go into work. I should think so too. The Health Secretary has got a six-million-long hospital waiting list to tackle.

I wonder, is Mr Javid aware of the further delays that an ongoing Covid fixation is causing in the NHS? One surgeon emailed me to express his alarm. A 66-year-old patient had arrived in hospital for heart surgery. Just hours before the operation, the poor man tested positive for Covid. Although he was not displaying any serious symptoms except, possibly, feeling tired the operation was cancelled.

That patients risk of death from surgical intervention has just risen to 90 per cent from an estimated 30 per cent directly because of the delay, fumes my source. I cannot believe that so many allegedly intelligent people are unable to make a sound judgment on the risk-benefit ratio of what is now just a flu.

Covid is no longer likely to kill you. But hospitals cancelling your operation or urgent appointment may well. The NHS needs to get a grip. We have nothing to fear but the fearful.

See more here:
It's cruel to deny trans children the chance to think again - The Telegraph

Recommendation and review posted by Bethany Smith

Eating a balanced diet and taking high-quality supplements can help support your body as you stop taking the pill.

Image Credit: LIVESTRONG.com Creative

What Really Happens to Your Body When examines the head-to-toe effects of common behaviors, actions and habits in your everyday life.

The side effects of starting hormonal birth control are pretty widely discussed. But there's a little more mystery about what happens to your body when stopping birth control.

Birth control pills, also known as oral contraceptive pills, are the second most common type of contraceptive method as of 2019 (the latest data available), per the Centers for Disease Control and Prevention (CDC). If you've been thinking about stopping birth control after being on the pill for years, you should know that it's safe to stop at any time, according to the Mayo Clinic. But you should expect your body to go through some changes.

Here's the scoop on the side effects of stopping birth control pills and tips for taking care of yourself as you make the transition.

When to Stop Birth Control Pills

There are several reasons why someone might want to stop using birth control pills. According to Felice Gersh, MD, ob-gyn and the founder/director of Integrative Medical Group of Irvine, those reasons include:

Your Period Could Become Irregular

While some people who menstruate go back to their normal periods soon after stopping birth control pills, other people may have irregular periods for a while.

"Even if ovulation resumes during the first cycle post-pill, there's no guarantee the next few cycles will be regular. In fact, it can take up to a year for their cycles to go back to regular," says Kerry-Anne Perkins, DO, ob-gyn and member of the medical review board of Women's Health Interactive. "This is true for both types of pills, progesterone or estrogen-free and combined hormonal, which has both estrogen and progesterone."

And if you took birth control in order to regulate your menstrual cycle, there's a chance that previous unpleasant period-related symptoms may make a return, she notes.

You may also notice a change in the flow and duration of your period, per the Cleveland Clinic. It may be longer and heavier birth control pills typically give you shorter and lighter periods.

Your Fertility Levels Could Be Lower

It's valid to have concerns about how your fertility may be affected by discontinuing birth control pills, especially if you are trying to become pregnant.

A July 2018 meta-analysis in Contraception and Reproductive Medicine found stopping contraceptive use doesn't significantly delay or negatively affect fertility.

But your fertility levels may also be lower than they were when you started taking birth control pills. "If you have been on birth control for many years, your fertility has naturally declined and may be significantly lower than when you started the birth control," Dr. Perkins says.

When stopping the pill, be sure to use a backup method of contraception if you aren't looking to get pregnant at all or right away, per the Cleveland Clinic.

You Could Lose or Gain Weight

The belief that oral contraceptives commonly cause you to gain weight is a longstanding one, per a January 2014 study in the Journal of Women's Health.

But researchers of the study found birth control pills weren't linked to short-term changes in weight or body composition after observing 150 people assigned female at birth (AFAB) with both normal weight and obesity who used oral contraception over three to four months.

Typically, the pill doesn't cause more than a pound of weight gain per year, according to the Cleveland Clinic.

There are chances that you can lose or gain weight after you stop taking the pill, though. "Some women retain water while on the pill, so if this is you, you may drop a couple of pounds after quitting it," Dr. Perkins says. "Others could retain water after quitting the pill, due to some temporary hormonal imbalances. Again, it shouldn't be more than a couple of pounds."

It's also possible to experience changes in appetite due to hormonal shifts, Perkins notes, that could in turn contribute to weight changes.

When to Talk to Your Doctor

Talk to your doctor if you have questions or concerns about what to expect when stopping birth control pills, per the Cleveland Clinic. That's also a good time to discuss how being off of the pill will affect any prior conditions you have.

You May Have Acne or Hair Loss

You have hormonal changes to thank for any adverse skin and hair-related side effects you may experience after you come off birth control pills. Quitting birth control pills leads to a temporary hormonal imbalance, according to Dr. Perkins.

"For example, acne is fairly common in the first few months post-pill," she says. Experiencing hair loss or a condition called hirsutism (excessive facial hair) is also possible.

You Might Experience Mood Shifts

Most people won't experience significant emotional changes related to stopping the pill; most of the effects are physical, per Jefferson Health. But if you experienced mood swings or emotional instability on birth control, those things may stop post-pill.

On the flip side, if you were prone to depression, anxiety and mood swings before using birth control pills, those conditions may return when you nix oral contraception, according to Oschner Health.

Your Sex Drive May Change

A September 2012 review in The Journal of Sexual Medicine found a small correlation between the use of hormonal contraceptives and decreased libido, however research shows there are mixed results overall on how hormonal birth control affects your sex drive.

If you experienced lower desire while on the pill, you could find yourself feeling more sexual than usual after you stop taking it. "After quitting the pill, you may also experience changes in your libido usually higher libido, especially around ovulation," Dr. Perkins says.

Stopping Other Types of Hormonal Birth Control

Here are some potential side effects of stopping other types of hormonal birth control, according to Dr. Perkins:

Tips to Help Make Stopping the Pill Easier

Many of the side effects of discontinuing your birth control pill are temporary, but there are things you can do to help ease them.

1. Take a High-Quality Multivitamin

A September 2016 study in The Journal of Clinical Endocrinology and Metabolism found an association between higher vitamin D levels and estrogen-containing contraceptive use among more than 1,600 people identified in the study as African American women.

It may be beneficial to focus on naturally increasing your nutrient levels after you're off the pill. Some ways to raise your vitamin D levels, per the Mayo Clinic, include:

Dr. Gersh also recommends supplementing if you can't fit enough crucial nutrients from your diet alone. "Taking a high-quality multivitamin is key. Be sure it contains methyl B12, methyl folate, selenium and the usual array of vitamins," she says. "Extra magnesium would be of benefit, along with omega-3s and vitamin D."

2. Finish Out Your Current Pill Cycle

While you can quit the pill cold turkey, it may be best to finish out your current pill pack before stopping altogether.

You can expect to have your period within a few days after stopping the pill if you stop in the middle of the current pill cycle, according to the Cleveland Clinic.

Try to finish out your current round of pills, if possible, to avoid messing with your period.

A balanced diet can help as you transition away from birth control pills. Eating well is especially important if your appetite is affected by stopping the pill. For example, you may experience cravings.

"Pay attention to those cravings and try to eat a healthy and balanced diet to minimize them, and you shouldn't have weight issues," Dr. Perkins says.

Original post:
What Happens When You Stop Taking Birth Control Pills - Livestrong

Recommendation and review posted by Bethany Smith

The report titled Adenomyosis Treatment market offers a primary overview of the Adenomyosis Treatment industry covering different product definitions, classifications, and participants in the industry chain structure. The quantitative and qualitative analysis is provided for the global Adenomyosis Treatment market considering competitive landscape, development trends, and key critical success factors (CSFs) prevailing in the Adenomyosis Treatment industry.

A number of estimations and calculations have been included in this market report by assuming a definite base year and the historic year. The report describes estimations of CAGR values, market drivers, and market restraints about this industry which is helpful for businesses in deciding upon numerous strategies. With this market report, you can effectively gain a holistic view of the market and then also benchmark all the companies in this industry. To win the competition in the global marketplace, going for this global market research report is necessary. This market report makes your organization armed with information produced by sound research methods.

Get Access to PDF Sample of Global Adenomyosis Treatment Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery @: https://globalmarketvision.com/sample-request/158723

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the market which would mention How the Covid-19 is affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adenomyosis Treatment Market Players to Combat Covid-19 Impact.

Some of the key players in the Global Adenomyosis Treatment Market are Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer.

Global Adenomyosis Treatment Market Segmentation:

Market Segmentation: By Type

Anti-inflammatory drugsHormone medicationsOther

Market Segmentation: By Application

HospitalClinicOthers

This comprehensive report provides:

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Retro Scooters Market in 2022.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Reasons to Purchase the report:

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Adenomyosis Treatment Analysis, Trends, Growth Factor

Chapter 5 Adenomyosis Treatment Application and Business with Potential Analysis

Chapter 6 Global Adenomyosis Treatment Segment, Type, Application

Chapter 7 Global Adenomyosis Treatment Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Adenomyosis Treatment

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Complete report on Adenomyosis Treatment Market report spread across 150+ pages, list of tables & figures, profiling 10+ companies. Read Detailed Index of Full Research Study at @ https://globalmarketvision.com/checkout/158723/single_user_license

If you have any special requirements, please let us know and we will offer you the report at a customized price.

About Global Market Vision

Global Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customers needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.

With our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.

Contact Us

Sarah Ivans | Business Development

Phone: +1-3105055739

Email: [emailprotected]

Global Market Vision

Website: http://www.globalmarketvision.com

Here is the original post:
Adenomyosis Treatment Market Analysis and Demand with Future Forecast to 2029 | Bayer AG, Ferring BV, Johnson & Johnson, Novartis Political Beef...

Recommendation and review posted by Bethany Smith

Its mid-afternoon on a mild spring day at Artemisia Clinic in Taos. Dr. Clara Wetmore, a doctor of Oriental Medicine, is treating Amy Dondanville, who has difficulty sleeping. Soothing music plays and fragrant herbs in orderly rows surround the treatment table of the well-lit clinic.

Wetmore consults with Dondanville and then checks her pulse at various points on her body, asking questions in a quiet voice, How is your stress level? Energy level? She asks how much caffeine Dondanville consumes.

Dondanville is experiencing a high level of stress, having just returned to her job as a clinical social worker after being gone for three weeks. She reports that she is not sleeping well and feels more frantic, like she is running on adrenaline that causes her to crash. She has removed most caffeine from her diet, drinking just one cup of black tea a day.

While Dondanville relaxes on the treatment table, Wetmore places needles in various parts of her body: her forehead, wrist, midsection and lower legs. I place needles at specific points along the relevant or affected meridians, based on symptoms, presentation and pulse diagnosis. Each point has unique indications, and I pick the points that relate to or address the symptoms and underlying health concerns, Wetmore explained. Today, she is inserting needles to help calm the mind, as well as reduce racing thoughts, anxiety, pain and insomnia. As the needles are placed, Dondanville explains that shes not feeling any pain, although sometimes she experiences a sensation.

Wetmore uses another tool, known as an ear or auricular seed, which is a tiny stainless steel pellet with a latex-free adhesive patch. Ear seeds are a type of auriculotherapy rooted in Chinese medicine. They're meant to promote comfort and relaxation and have become very popular in the West in recent years, despite some disagreement among medical professionals as to their efficacy. Occasionally, Wetmore uses gold pellets, depending on the treatment, or even small pellets with crystals on the top that look like little earrings if brought in by a patient.

Wetmore cleans and disinfects the ear and then places the tiny pellets in specific spots on the left ear that are tender, indicating trouble somewhere in the body. Dondanville will wear them for a week, after which they fall out or she will remove them. The ear seeds do their work while in place, Wetmore says, and their effectiveness can be increased by periodically pressing on them. Right now, I am placing an ear seed to regulate the nervous system and treat an insomnia point," she explains. "I also checked the liver point, usually aggravated by stress but that spot wasnt tender, so I am moving on to the heart spot which is calming to the mind.

Dondanville is experiencing difficulty powering down and falling asleep, which is her most common sleep struggle, although she does sometimes wake up in the middle of the night and have a hard time going back to sleep. She usually comes in weekly, but since she has been out of town, this is her first appointment in almost a month. She says, Ive had chronic sleep problems since I was a kid; its always been a struggle for me. The practice of coming regularly allows me to connect with my body and speak to what is specifically happening with my digestion, sleep, mood and energy levels. The act of reflecting is helpful itself. When accessing treatment regularly, I find I can fall asleep with great ease, which I wasnt previously able to achieve.

Wetmore also gives Dondanville a Chinese herbal formula for sleep. At the beginning of treatment, she was taking three to four doses per night and that has been reduced to one or none. This is what I want for all my patients: to get to the point where their bodies remember how to sleep without external help, says Wetmore.

Dondanville has been seeing Wetmore for about two and a half years. She sought Wetmore out for help with another issue, but through the comprehensive check-ins done at each appointment, the two discovered the extent of Dondanvilles sleep disturbances. The practice of attending appointments and engaging in reflection has created a sense of mindfulness and awareness about what is happening outside appointments and brought a deeper sense of noticing about which routines and habits nurture my body and which ones harm them, reflects Dondanville.

When asked what advice she would give to people struggling with sleep problems, Dondanville recommends that people become aware of what content is stimulating to the brain in a negative way, whether it be watching TV, listening to audio recordings or scrolling on the phone.

According to a study by Harvard Medical School, the blue light emitted by smartphones "can affect your sleep and potentially cause disease." The study notes a well-known fact about the brain that the absence of light signals to the brain to shut down for sleep and the presence of light triggers wakefulness. As such, turning down any bright lights before bed can help people to achieve deeper sleep. Conversely, exposure to daylight upon waking can boost alertness and mood.

Wetmore added, Id suggest that people establish a routine that cues the body that it is time to move towards sleep, which might be stretching, taking a bath or shower, or applying cream to nurture the body.

Sleep disorders and effective treatment

Wetmore opened her practice five years ago. She earned a Master's of Science in Oriental Medicine degree from the Southwest Acupuncture College in Santa Fe and is licensed by the state and certified nationally. For the best results, she sees patients on a regular basis, but even a single treatment can help. One new patient who was skeptical of acupuncture came to see Wetmore to get help with her racing thoughts. Wetmore treated her with acupuncture, ear seeds and an herbal formula. When Wetmore saw the patient next, she had gone from sleeping for about an hour a night to sleeping seven hours. Sometimes its dramatic like that, and other times it can take weeks or months to see results like hers, says Wetmore.

More than 100 different types of sleep disorders have been identified, according to the Sleep Foundation. Wetmore sees many of them at her clinic. People come to me with sleep issues ranging all over the insomnia spectrum; some who cant fall asleep, some who cant stay asleep or wake up too early, some light sleepers, some with crippling nighttime anxiety, some who cant turn their minds off at night," she says. "Some patients sleep for a few minutes per night if at all some for a few hours and some just dont get quite enough for their particular needs. The causes range from trouble sleeping due to menopausal or perimenopausal hormone shifts, which account for about half of her patients, while others are dealing with stress, anxiety, trauma, grief, pain or other issues. Sometimes, there is no obvious cause.

Because sleep disorders are so unique to each individual, being able to tailor acupuncture treatments and herbal formulas to each patients needs is hugely important in my work, says Wetmore. My goal is to regulate the sleep cycle so that patients dont need to take herbs and supplements forever to get a good nights sleep. Its like giving a gentle nudge and reminder for the body to remember how to do such a fundamental and necessary regenerative process on its own. Another advantage is that I spend a lot of time with each patient, so I really get to know each persons life, physical health and emotional health, giving me the insight to treat very specifically.

As part of her approach, Wetmore checks for any medications being taken by the patient to make sure there wont be interactions between the medications and herbs she recommends for sleep. In addition to making recommendations about nutrition, Wetmore refers patients to other needed services, such as therapy, meditation, exercise, primary care and other physicians.

When asked how her approach is different than a medical doctors might be, Wetmore said, In some ways, my approach probably isnt all that different than that of Western medicine; were all trying to help people feel better, and are using the tools, knowledge and skillsets we have. I have tremendous respect for my medical colleagues, and although folks dont always expect it, Im very much in support of Western medicine and science, and love to work in tandem with my patients other providers.

The questions of how much sleep we need as humans and how the lack of sleep impacts our health are the subjects of numerous studies over the past few years. In his 2017 book, Why We Sleep, Matthew Walker, Ph.D., professor of neuroscience and psychology at UC Berkeley and the director of the Center for Human Sleep Science, reports that two-thirds of the adults in developed nations do not get the full eight hours of recommended sleep. Through his research, he has pioneered work showing that insufficient sleep depresses the immune system, doubles risk of cancer, adds to weight gain and is a key factor in whether or not a person will develop Alzheimers disease. To find out more and see tips for better sleep, visit masterclass.com/articles/matthew-walker-on-improving-sleep-quality. There are also several free podcasts featuring Walker that delve into his research.

Here is the original post:
Chinese medicine and the pursuit of a good night's sleep - taosnews

Recommendation and review posted by Bethany Smith

New York, United States A2Z Market Research published new research on Global Osteoporosis Treatment covering the micro-level of analysis by competitors and key business segments (2022-2029). The Global Osteoporosis Treatment explores a comprehensive study on various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing.

Some of the Major Key players profiled in the study are Merck & Co AGNovartis AGEli Lilly and CompanyAmgen, Inc.Allergan PlcActavis Plc.Pfizer, Inc.GlaxoSmithKline Pharmaceutical Ltd.F. Hoffmann La Roche Ltd.Novo Nordisk A/STeva Pharmaceuticals Industries Ltd.

Get PDF Sample Report + All Related Table and Graphs @:

https://www.a2zmarketresearch.com/sample-request/584373

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Osteoporosis Treatment market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitutes, and the degree of competition prevailing in the market.

Key market aspects are illuminated in the report:

Executive Summary: It covers a summary of the most vital studies, the Global Osteoporosis Treatment market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.

Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Osteoporosis Treatment market, the years measured, and the study points.

Company Profile: Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.

Manufacture by region: This Global Osteoporosis Treatment report offers data on imports and exports, sales, production and key companies in all studied regional markets

Global Osteoporosis Treatment Market Segmentation:

Market Segmentation: By Type

BisphosphonatesParathyroid Hormone TherapyCalcitoninSelective Estrogen Inhibitors Modulator (SERM)

Market Segmentation: By Application

HospitalsClinicOthers

Market Segmentation: By Geographical Analysis

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get Special pricing with up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount/584373

The cost analysis of the Global Osteoporosis Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in the report include:

Table of Contents

Global Osteoporosis Treatment Market Research Report 2022 2029

Chapter 1 Osteoporosis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Osteoporosis Treatment Market Forecast

Buy the Full Research Report of Global Osteoporosis Treatment Market @: :

https://www.a2zmarketresearch.com/checkout

If you have any special requirements, please let us know and we will offer you the report as you want. you can also get individual chapter-wise sections or region-wise report versions like North America, Europe or Asia.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Continued here:
Osteoporosis Treatment Market See Huge Growth for New Normal | Merck and Co AG, Novartis AG, Eli Lilly and Company Bloomingprairieonline -...

Recommendation and review posted by Bethany Smith

The SARS-CoV-2 virus can infect specialized pacemaker cells that maintain the hearts rhythmic beat, setting off a self-destruction process within the cells, according to a preclinical study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and NYU Grossman School of Medicine. The findings offer a possible explanation for the heart arrhythmias that are commonly observed in patients with SARS-CoV-2 infection.

In the study, reported March 8 in Circulation Research, the researchers used an animal model as well as human stem cell-derived pacemaker cells to show that SARS-CoV-2 can readily infect pacemaker cells and trigger a process called ferroptosis, in which the cells self-destruct but also produce reactive oxygen molecules that can impact nearby cells.

This is a surprising and apparently unique vulnerability of these cellswe looked at a variety of other human cell types that can be infected by SARS-CoV-2, including even heart muscle cells, but found signs of ferroptosis only in the pacemaker cells, said study co-senior author Dr. Shuibing Chen, the Kilts Family Professor of Surgery and a professor of chemical biology in surgery and of chemical biology in biochemistry at Weill Cornell Medicine.

Arrhythmias including too-quick (tachycardia) and too-slow (bradycardia) heart rhythms have been noted among many COVID-19 patients, and multiple studies have linked these abnormal rhythms to worse COVID-19 outcomes. How SARS-CoV-2 infection could cause such arrhythmias has been unclear, though.

In the new study, the researchers, including co-senior author Dr. Benjamin tenOever of NYU Grossman School of Medicine, examined golden hamstersone of the only lab animals that reliably develops COVID-19-like signs from SARS-CoV-2 infectionand found evidence that following nasal exposure the virus can infect the cells of the natural cardiac pacemaker unit, known as the sinoatrial node.

To study SARS-CoV-2s effects on pacemaker cells in more detail and with human cells, the researchers used advanced stem cell techniques to induce human embryonic stem cells to mature into cells closely resembling sinoatrial node cells. They showed that these induced human pacemaker cells express the receptor ACE2 and other factors SARS-CoV-2 uses to get into cells and are readily infected by SARS-CoV-2. The researchers also observed large increases in inflammatory immune gene activity in the infected cells.

The teams most surprising finding, however, was that the pacemaker cells, in response to the stress of infection, showed clear signs of a cellular self-destruct process called ferroptosis, which involves accumulation of iron and the runaway production of cell-destroying reactive oxygen molecules. The scientists were able to reverse these signs in the cells using compounds that are known to bind iron and inhibit ferroptosis.

This finding suggests that some of the cardiac arrhythmias detected in COVID-19 patients could be caused by ferroptosis damage to the sinoatrial node, said co-senior author Dr. Robert Schwartz, an associate professor of medicine in the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and a hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center.

Although in principle COVID-19 patients could be treated with ferroptosis inhibitors specifically to protect sinoatrial node cells, antiviral drugs that block the effects of SARS-CoV-2 infection in all cell types would be preferable, the researchers said.

The researchers plan to continue to use their cell and animal models to investigate sinoatrial node damage in COVID-19and beyond.

There are other human sinoatrial arrhythmia syndromes we could model with our platform, said co-senior author Dr. Todd Evans, the Peter I. Pressman M.D. Professor of Surgery and associate dean for research at Weill Cornell Medicine. And, although physicians currently can use an artificial electronic pacemaker to replace the function of a damaged sinoatrial node, theres the potential here to use sinoatrial cells such as weve developed as an alternative, cell-based pacemaker therapy.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosurespublic to ensure transparency. For this information, see profiles for Dr. Todd Evans, and Dr. Robert Schwartz.

See the original post:
Are COVID-19-Linked Arrhythmias Caused by Viral Damage to the Heart's Pacemaker Cells? - Weill Cornell Medicine Newsroom

Recommendation and review posted by Bethany Smith

The following is management's discussion and analysis ("MD&A") of certainsignificant factors that have affected our financial position and operatingresults during the periods included in the accompanying financial statements, aswell as information relating to the plans of our current management. This reportincludes forward-looking statements. Generally, the words "believes,""anticipates," "may," "will," "should," "expect," "intend," "estimate,""continue," and similar expressions or the negative thereof or comparableterminology are intended to identify forward-looking statements. Such statementsare subject to certain risks and uncertainties, including the matters set forthin this report or other reports or documents we file with the Securities andExchange Commission from time to time, which could cause actual results oroutcomes to differ materially from those projected. Undue reliance should not beplaced on these forward-looking statements which speak only as of the datehereof. We undertake no obligation to update these forward-looking statements.

The following discussion and analysis should be read in conjunction with ourfinancial statements and the related notes thereto and other financialinformation contained elsewhere in this Form 10-K

Our Ability To Continue as a Going Concern

--------------------------------------------------------------------------------

Index

Biotechnology Product Candidates

GENERAL AMERICAN CAPITAL PARTNERS

--------------------------------------------------------------------------------

Index

Results of Operations Overview

Comparison of Years Ended December 31, 2021 and December 31, 2020

Cost of sales consists of the costs associated with the production of MyoCathand test kits, product costs, labor for production and training and lab andbanking costs consistent with products and services provided.

Cost of sales was $52,030 in the year ended December 31, 2021 compared to$64,117 in the year ended December 31, 2020. The decrease is due to the decreasein revenues.

Research and development expenses were $0 in 2021 remaining the same as $0 in2020.

Selling, General and Administrative

Gain (loss) on settlement of debt

--------------------------------------------------------------------------------

In valuing our common stock, our Board of Directors considered a number offactors, including, but not limited to:

--------------------------------------------------------------------------------

Index

Options outstanding at December 31, 2021 110,643,884 $ 0.0247

Options exercisable at December 31, 2021 93,491,384 $ 0.0256

Available for grant at December 31, 2021 34,168,070

Average Number Weighted Average

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Index

Our primary sources of revenue are from the sale of test kits and equipment,training services, patient treatments, laboratory services and cell banking.

Patient treatments and laboratory services revenue are recognized when thoseservices have been completed or satisfied.

Research and Development Costs

--------------------------------------------------------------------------------

Depreciation is computed using the straight-line method over the assets'expected useful lives or the term of the lease, for assets under capital leases.

Cash and cash equivalents include cash on hand, deposits in banks withmaturities of three months or less, and all highly liquid investments which areunrestricted as to withdrawal or use, and which have original maturities ofthree months or less.

We allocate the proceeds received from equity financing and the attached optionsand warrants issued, based on their relative fair values, at the time ofissuance. The amount allocated to the options and warrants is recorded asadditional paid in capital.

Selling, General and Administrative

Our opinion is that inflation has not had, and is not expected to have, amaterial effect on our operations.

Liquidity and Capital Resources

In 2021, we continued to finance our operational cash needs with cash generatedfrom financing activities.

Economic Injury Disaster Loan (EIDL)

--------------------------------------------------------------------------------

Net cash provided by investing activities was $0 for the year ended December 31,2021.

Existing Capital Resources and Future Capital Requirements

As of December 31, 2021, we had $8,016,314 in outstanding debt, net of debtdiscount of $273,216.

Off-Balance Sheet Arrangements

Recent Accounting Pronouncements

Refer to Note 1. Organization and Summary of Significant Accounting Policies inthe notes to our financial statements for a discussion of recent accountingpronouncements.

Edgar Online, source Glimpses

Excerpt from:
U.S. STEM CELL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com

Recommendation and review posted by Bethany Smith

According to The Insight Partners new research study on Epithelial Cell Culture Media Market Forecast to 2027 COVID-19 Impact and Global Analysis by Product Type and End User, the market is expected to reach US$ 303,040.33 thousand by 2028 from US$ 128,155.95 thousand in 2020; it is estimated to grow at a CAGR of 11.4% from 2021 to 2028.

Certain age-related diseases, abnormalities, and trauma damage the tissues and organs. Regenerative medicines have the potential to replace or heal tissues and organs, along with normalizing congenital defects. In the last decade of the century, tissue engineering techniques have emerged impressively, and they are now being employed in broader areas of regenerative medicine. Thus, it has now become possible to use these techniques in the development of clinical therapies for the maintenance, repair, replacement, and enhancement of biological functions. Further, the regenerative medicines developed using cell-based models can potentially assist researchers in the early intervention of degenerative diseases and traumatic injuries.

Download sample PDF Copy of Epithelial Cell Culture Media Market study at: https://www.theinsightpartners.com/sample/TIPRE00022539/

PromoCell GmbH; Merck KGaA; ATCC; AXOL Bioscience Ltd.; Thermo Fisher Scientific, Inc.; Bio-Techne Corporation; Celprogen, Inc.; Lonza Group AG; HiMedia Laboratories; and Cell Biologics, Inc. are among the leading companies operating in the epithelial cell culture media market.

Geographically, the epithelial cell culture media market is segmented into North America, Europe, Asia Pacific (APAC), the Middle East and Africa (MEA), and South and Central America (SCAM). North America held the largest market share in 2020. In 2020, the US held the largest share of the market in North America. The market growth in North America is attributed to the key driving factors such as the presence of various market players and increasing demand for cell culture products from biopharmaceutical and biotechnology companies.

Human amniotic epithelial cells (hAECs) from placental tissues have gained substantial attention in the field of regenerative medicine owing to their proliferative capacity, easy access, multilineage differentiation potential, and safety. These are perinatal stem cells that have embryonic stem cell-like properties and the capability to be induced to differentiate. Thus, a growing focus on bringing advancements in regenerative medicine is likely to boost the adoption of epithelial cell cultures, thereby bolstering the demand for the respective culture.

Inquiry Before Buying on epithelial cell culture media market at: https://www.theinsightpartners.com/inquiry/TIPRE00022539/

Below is the list of the growth strategies done by the players operating in the epithelial cell culture media market:

In May-21 Bio-Techne has released MimEX GI, a new product line for generating 3-dimensional (3-D) gastrointestinal tissue on a 2-D surface.

In Sep-2020 Axol Bioscience and Censo Biotechnologies Announce Merger. The newentitywould become a global leader in the iPSC-based neuroscience, immune cell, and cardiac simulation industries for drug development and screening.

The report segments the epithelial cell culture media market as follows:

By Product Type

Human Mammary Epithelial CellsBronchia/Trachea Epithelial CellsRenal Epithelial CellsOthers

By End User

Biopharmaceutical CompaniesAcademic and Research Laboratories

Interested in Purchasing epithelial cell culture media market Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00022539/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Continued here:
Epithelial Cell Culture Media Market to exceed USD 303040.33 thousand by 2028 says, The Insight Partners - Digital Journal

Recommendation and review posted by Bethany Smith

It seems bizarre that in 2022, some biotech companies interested in doing something about aging are still saying that they are not. Cellular rejuvenation seems to be the latest buzzword and an attempt to rebrand and escape the stigma of anti-aging.

Recently, researchers at the Salk Institute, in collaboration with Genentech, showed that they can safely and effectively reverse aging in old mice by resetting their cells to a more youthful state using Yamanaka factors.

Genentech, a large Roche subsidiary biotech company, is focusing on cellular rejuvenation using partial cellular reprogramming. It could be set to become a future rival of Altos Labs.

Earlier this year, Altos Labs made its debut, bringing $3 billion in funds and an impressive roster of researchers to focus on cellular reprogramming. Despite media suggestions that it is a longevity or anti-aging company, Altos is adamant that it is not.

Instead, Altos has positioned itself as a cellular rejuvenation reprogramming company. Genentech also looks like it might follow a similar path and double down on the cellular rejuvenation angle, avoiding coming out and saying that it is an anti-aging or longevity company. Given that both companies are working on cellular rejuvenation, which is very much relevant to aging, it might seem somewhat strange for them to claim to be uninvolved in it.

Why are they doing this? Its because life extension and anti-aging have a branding problem. There are a few reasons why.

Some companies are sidestepping the whole issue by simply going after diseases without drawing focus on the age reversal aspect of what they are doing. The FDA is not going to approve a trial to reverse aging, so the logical step for a number of companies is to instead focus on a particular disease and aim to demonstrate disease modification. The FDA is unlikely to take issue with age reversal or rejuvenation technology if it is demonstrably effective against a specific age-related disease. This is why an increasing number of companies are taking this route to get through clinical trials. Once approved the idea would be that off label use would occur.

The life extension community unfortunately does have a reputation for being long on promises and short on delivery. With what is now decades of research, there are still no effective therapies against aging.

Of course, science takes time, and a lot of progress is being made in our fundamental understanding of aging as well as the steady slog to translate the research from animals to humans. However, public perception is based on results, and so far, nothing has turned back aging enough in people to grab public attention.

This is also not helped by otherwise earnest researchers in our community sometimes fueling hype and exaggerating the impact of their current research. While it is perfectly understandable to be excited about ones own research, some researchers do sometimes make claims that go beyond the data.

This is likely due to their hopes of attracting funding and grants, but it can be harmful to the image of the field when the hype does not meet the reality.

Another factor that is likely playing a part in this rebranding is the sad fact that our field is filled with snake oil salesmen out to make a quick buck.

Alongside the legitimate researchers doing fine scientific work in the lab, there are also plenty of hucksters hiding in the community. These people prey on people who lack the knowledge to discern credible science from pseudoscience and peddle worthless products, much like the snake oil salesmen of the Old West.

One example is a biotech company evading the FDA by setting up shop in a country with few or no regulations. This sort of company makes bold claims yet never delivers on those claims in practice, using poorly designed experiments and tiny cohorts that are statistically irrelevant.

Worse, such a company might not even attempt to publish data in credible scientific journals, instead choosing to make bold claims on personal websites and publishing dubious data that has not gone through peer review. This sort of company sometimes offers treatments in areas with little or nonexistent regulations. Its customers are gambling with their lives in the hope that whatever the company is offering is as described and actually works as intended; they could be receiving a fake, saline injection or something worse.

Another example is a supplement peddler who sells expensive supplement blends with flashy names, which, on inspection, turn out to be commonly available herbs and minerals that are mixed and sold at a high mark-up with questionable or no supporting data. These sorts of people have plagued our community and given the field a reputation for snake oil. Therefore, it is no surprise that these new, well-funded companies working on cellular rejuvenation want nothing to do with it.

It will take a group effort to clean up the perception of our field to hopefully make these new companies more comfortable in associating with it. There are a few things that each of us can do to help.

While it will be some years yet before a comprehensive suite of therapies to end age-related diseases is here and available, and the hucksters are peddling their wares right now, you can arm yourself with knowledge and protect yourself and our community from these people. Learn to evaluate science rather than taking things at face value, and avoid expensive scams and bad science.

Here are some useful questions to consider when reading an article, looking at claims made by supplement makers, or evaluating any science in general.

Legitimate claims will undergo peer review first. Shady companies not backing up their claims with published data are a dime a dozen; do not be fooled by them. Also, pay attention to the source of the news; press releases, associated companies, and obscure websites are poor sources. The bottom line is that any company making claims about its product should be able to back those claims up with published research in a respected journal.

Credible research is generally published in credible, peer-reviewed journals with transparent and clear details of experiments so that others may attempt to replicate their results. When evaluating a claim, always see if it is published and if anyone else has successfully, independently replicated the results. Also, ensure that any independent results are indeed independent and that there is no link between the original group and the study replicating the results.

Similar to the above; a company or research team worth its salt will have a trail of evidence documenting research and development efforts that likely go back for years or even decades. If a company appeared from nowhere and has no historical record of its research, this is a huge red flag.

Learn to evaluate how statistically significant results are. Did a test involve a single mouse or a person, or did it involve hundreds or even thousands of test subjects to reach its conclusion? The smaller the study, the higher the statistical noise and the greater the effect that outliers can have on the average. Large test groups offer the most stable and accurate data, and small, single-patient studies are, for the most part, not useful.

Beware a company that tests on a single candidate and claims that a supplement or therapy works. A credible company may start with a small pilot study but ultimately expands into larger-scale studies in order to prove safety and efficacy.

Investigate and check their academic pedigrees. Having a Ph.D. is not required to conduct great science, but, in general, a researcher of any worth will have peer-reviewed publications with lots of citations and a good reputation in academia.

Even when there is published data, make sure you find out where the funding comes from. Studies on a patented supplement that are funded by the patent holder are a serious red flag and should be viewed with extreme caution.

Claims of being suppressed or somehow blocked by the government or other entities is a common tactic used by scammers. A scammer might claim to be a misunderstood researcher who just wants to help, and a supplement maker in trouble with the FDA for making false claims might say that it is simply being misinterpreted. This is base trickery; dont fall for it.

If it sounds too good to be true, then the chances are that it probably is. Credible science is always appropriately cautious and never overly affirmative; if someone is way too positive, this is a red flag.

The appeal to the ancients logical fallacy is commonly used to convince and part people from their money. The ancients used certain supplements, so they must work is a common tactic used to sell things. The truth is that while our ancestors were indeed clever and creative in many ways, not all their ideas were wise; indeed, many of the things they believed were dead wrong and even dangerous. This is a commonly used tactic in the supplement and diet industries.

This is the appeal to nature fallacy, another common sales tactic that takes advantage of the biases we as humans have and our inclination to think that everything natural is good. A quick review shows us that what is natural is not always a good thing: tidal waves, earthquakes, venomous snakes, diseases, and aging are all natural, but they are most certainly not desirable.

This is, of course, only a short checklist of things to watch out for; if a claim raises these flags, then its a good idea to be highly dubious about its credibility.

The snake oilers will be with us for quite a while, but by working together as a community and thinking critically about claims, we can help filter these people out and ultimately clean up the field for the benefit of legitimate scientists working on the real solutions to aging that will benefit us all.

Another consideration is that as more therapies enter clinical trials and high-quality data arrives, the hucksters will be steadily ousted. Ultimately, once therapies that have passed through the proper trial process arrive, most people will not wish to risk their health and money on hucksters.

The reputation of the field has improved massively in the last decade, but there is much that we can all do to improve it further.

Continue reading here:
Life Extension and Anti-Aging Have a Branding Problem - Lifespan.io News

Recommendation and review posted by Bethany Smith

Raiany Romanni is a Harvard Kennedy Fellow in Effective Altruism, an A360 Scholar, a Stanford Existential Risk Fellow, and a bioethicist. She is currently working on a non-fiction book aimed at catalyzing the ethics of longevity research while suggesting that aging is the costliest of all human diseases. Raiany says that of particular interest to her works is the human proclivity towards death-embracing narratives and its harmful effects on economies and societies.

The easy answer would be to point at my degree in bioethics from Harvard Medical School. The more accurate answer, however, would be to say that I became a bioethicist because Ive always been obsessed with life. What does it mean to be alive or dead? How have the meanings we ascribe to life evolved over the centuries? My training in philosophy seemed insufficient to address these questions. Theory is only useful if we can translate it to the suffering of real persons and to the emerging world of converging technologies which will transfigure the meaning of life.

We need bioethicists around because what is right isnt always intuitive, and it takes rigorous work to understand how best to augment human flourishing. As a bioethicist, I try to occupy myself with what is quantifiably good for human societies. I recently became a Harvard Kennedy Fellow in Effective Altruism (EA) and believe EA supplements the work of bioethics by encouraging counterintuitive questions like What if we treated the fundamental processes of aging, instead of Alzheimers? Would that objectively be a better use of our limited resources towards our existing goal of extending human healthspan?

We currently spend a little over 1% of all National Institutes of Health funding on the fundamental processes of aging. Meanwhile, some 80% of an average individuals medical expenses occur past the age of forty. Theres a significant mismatch here.

For all our medical breakthroughs, two things have remained rather constant throughout history: human lifespan and human healthspan. For every human life, we have consistently recorded one death, at a maximum age of 122. At around 25, we begin to decay. These two facts often overshadow the remarkable fact that weve engineered a doubling in average life expectancy over the past century.

The eradication of smallpox and polio and the relative control of nearly all infectious diseases was hardly insignificant. But the fact that we havent doubled the number of years a human can live let alone in good health legitimately contributes to the publics disbelief that scientists may be able to achieve this.

Were wired to appreciate the world through an availability heuristic: the examples we can most readily recall often guide our moral reasoning. So, its not altogether irrational that people should question our ability to reverse aging. Only a small fraction of the worlds population devotes their time to reading dense, scientific papers, which indeed prove that several mechanisms of aging can be quite easily manipulated. And only a small fraction of the worlds population wants to deal with the ethical challenges that accompany this fast-arriving revolution.

Weve built so much of our infrastructure around the idea of death and gradual decay that most of us would rather just reject the messy possibility of a longer, healthy life. It seems like too much work. With radical health extension, what do we do about incarceration or monogamy? These are difficult questionsbut certainly worth answering.

As a myth, the notion that death is a progress-furthering entity, and aging a necessary parcel of life, made sense. For millennia, it was a helpful narrative, needed to cope with the gruesomeness of bodily decay, when we could do nothing about it. We certainly didnt have the converging technologies, when the Black Plague killed a good half of the European population, to hope otherwise. In that context, religion, too, was a rational choice.

Responding from a place of recognition of the publics rationality, rather than the (misguided) assumption that people reject longevity research because they are irrational, is helpful, I think. People rely on heuristics to do their own scanning of the world, and those can be misleading at times, but I like to believe that if offered a full picture of the problem of aging, a good portion of us would be convinced it must be solved.

The ethics, in my view, cant be considered without consideration of the economic, downstream effects. If you think ethics ought to be addressed without regard to economic impact, then you cant talk about equitable distribution, affordability, or even the creation of these therapies in the first place (which, whether theorists like it or not, requires money).

We cant reduce the ethics to just economics: a mistake often made when bioethicists assume that biotechnologies should only be pursued if they can be made immediately affordable. But we also cant undermine the fact that increased capital can translate directly into increased human flourishing.

To be relevant (i.e., not constantly outpaced by the science), I think bioethicists must learn to consider technologies in principle: to assume that they could work, could be quite equitably distributed (not in ideal, Rawlsian worlds, but in the flawed societies weve got), and could go through all phases of a clinical trial. Then, we get to truly interesting questions.

If we could engineer ourselves out of aging, would we risk engineering ourselves, too, out of the meaning of human life? The answer, I think, is yes: but only as much as we engineered ourselves out of the meaning of life in the Stone Age, when to be human meant to hunt and gather for ones every mealuntil it didnt.

First, I think the wealthy should be rewarded for funding these life-saving technologies towards clinical safety, and eventually towards governmental adoption. If there is no reward, there are no therapies, no trickle-down effect, no decreased human suffering.

The sad part, for me, is that venture capital alone, absent governmental funding, is going to take decades, if not centuries, longer to deliver commercial-grade aging therapies. Imagine for a minute that for some odd reason governments decided during the COVID-19 pandemic that they would leave it all to private capital. Wed probably get to a vaccine, and to some level of social relief, but not within the span of several months.

Again, only about 1% of all National Institutes of Health funding goes to fundamental aging research. So, at least we have people like Bezos and Thiel and Zuckerberg interested in disrupting the healthcare system. I hope they do: wed all benefit from it.

Im interested in increased human flourishing, and diminished suffering. Whether a civilization that could repeatedly reset its biological clock could achieve both is a question at least worth pursuing.

Weve built our entire infrastructure to sustain rather than solve the problem of aging. Nick Bostroms The Fable of the Dragon Tyrant is a brilliant caricature of this problem. If we could always return to a more youthful state say, like Turritopsis dohrnii I think wed be incredibly productive. The US currently spends nearly half its federal budget every year on the effects of aging. Imagine the problems we could solve if that funding were freed up, and there will be no shortage of problems.

But then, would innovation take place at a similar rate? Some studies show that people are most productive in their fortieswhen theyve lived enough years to know what they are doing, but not enough that their cells cant remember what they used to be. If the same person were in charge of innovation, say, through a two-hundred-year health-span, would they be prone to founding startups, and coming up with fresh solutions to old problems? I think wed need to actively train this new civilization on the importance of remaining nimble, and not carrying biases. This may not be so easily achieved, but if the alternative is murdering these people, or burdening our healthcare systems, I think we all agree it would be well worth the effort.

So, yes, if we engineer ourselves out of aging, we will most likely engineer ourselves, too, out of the meaning of life. This would be neither the first nor the last time in history this happened. Were the storytellers. The difference, in this century, is that the story is going to evolve at an unprecedented pace.

The cause isnt ours: its humanitys. Health extension is a more effective way of doing what weve been doing all along: namely, extending life and health, and delaying death and decay.

Soon, our populations will begin to shrinkJapan, for example, is set to lose 21 million people by 2050. And, as Peter Diamandis writes, in technologically advanced societies, where misdistribution and not scarcity of resources is the issue, large populations are an asset. The more minds working towards human and planetary flourishing, the better.

Link:
Raiany Romanni on the Ethical Aspects of Life Extension - Lifespan.io News

Recommendation and review posted by Bethany Smith

Essex National Heritage Area Chief Executive Officer Annie C. Harris.

The Essex National Heritage Area, created in 1996 as an unusual national park, will continue to receive federal financial support this year as legislators recently approved a spending bill continuing the designation until 2023.

Federal law authorizing the secretary of the interior to provide money to the Essex National Heritage Area expired last Sept. 30. The countywide park emphasizes the historical significance of the 500-square-mile region, covering 34 cities and towns.

Two and a half decades after its creation, the Essex National Heritage Area continues to serve as a cultural and economic driver for working families throughout the region and for communities like Lawrence, Haverhill and Andover, said Congresswoman Lori Trahan in a joint legislative statement.

Sen. Edward J. Markey said he is glad the spending bill heeded our call to extend the Essex National Heritage Areas authorization, enabling it to receive the federal funds it needs to continue to support partnerships between Massachusetts communities and the National Park Service to preserve our regional treasures. He added he will continue fighting in the Senate to lift the funding cap for the Essex National Heritage Area and extend its authorization even further until 2036.

U.S. Rep. Seth Moulton added, The Essex National Heritage Area brings hundreds of thousands of people to northeast Massachusetts, where they spend millions of dollars and create thousands of jobs in our community.

Last year, Sens. Markey and Elizabeth Warren and Reps. Moulton and Trahan introduced legislation to eliminate the total funding cap for the Essex National Heritage Area and extend its authorization by 15 years to 2036. In November 2021, the Senate Energy and Natural Resource Committee passed a version of the bill that would raise the heritage areas funding cap to $22 million and extend its authorization to 2036.

Like Loading...

Related

Continue reading here:
Essex National Heritage Area Gets Life Extension with Approval of Federal Spending Law - WHAV News

Recommendation and review posted by Bethany Smith

The average guy lives to be 75 years old. Thats up about five years from what our life expectancy was two decades ago. The even better news: There are also fairly easy ways to make the most of the time you've already gainedand probably earn even more of it. We're talking about small lifestyle or outlook changes with big impacts. Because your real goal shouldn't be just to live longer, but to feel more vital.

To prove it, Mens Health asked a fleet expertseveryone from longevity and healthy aging researchers, to top athletes and cultural iconsto share their own practical advice for carpe deiming. Here are 14 easy ways to help you extend and enhance your life. Starting right now.

Exercising random acts of kindness and donating time to good causes enhance social integration while improving self-gratification. Those factors, plus the stress relief those things create, can have profound longevity benefits.

James Muruthi, Ph.D., Director of the Healthy Aging Lab at University of Oregon.

Feed on Fiber

Eating fibrous foods like yams and asparagus and polyphenol rich foods like olive oil, coffee, tea, and dark colored fruits and vegetables produces a hugely beneficial phenomenon called mitochondrial uncoupling in our cells. Healthy old people have the most uncoupled mitochondria. This mitochondrial energy processing trick is the golden ticket to increasing energy levels, losing weight and yes, extending your lifespan.

Steven Gundry, M.D., former cardiac surgeon and author of The Longevity Paradox: How to Die Young at Ripe Old Age and Unlocking the Keto Code.

Respond Instead of React

"Slowing aging starts with slowing down. Cultivate a space between a stimulus (stress, unhealthy food cravings) and your response by going for a walk or taking ten deep breaths through your nose and out of your mouth. These activities will activate the vagus nerve and parasympathetic nervous system, which will allow you to make choices from a place of clarity and certainty, helping you make healthier choices for your body in the long run.

Kien Vuu, M.D., clinical professor at UCLA Health and author of Thrive State: Your Blueprint for Optimal Health, Longevity, and Peak Performance.

People with severe mental health disorders tend to die earlier than the general population, and taking charge of your mental wellbeing can do wonders for life extension. One way to start: Answer these questions right now: 1) How is my mood? (Answer with an emotion. Am I happy? Sad? Angry? Upset? Irritable? Euphoric? 2) Is this your baseline or normal mood? (Answer yes or no, because we all have off days. If its an off day, reevaluate later in the week or the following week.) 3) Am I content with feeling this way? If no, reach out to someone you trust to talk about it.

Kalisha Bonds Johnson, Ph.D., R.N., professor at Emory Universitys School of Nursing, director of special programs at Black in Gerontology & Geriatrics.

Cold exposure releases noradrenaline, a hormone that boosts cell performance. Due to the disappearance of thermal stress thanks to air conditioning and central heating, our bodys thermoregulatory system isnt getting enough of the exercise or stimulation needed to feel invigorated and perform better. Through daily cold water immersion, you can boost your bodys natural repair and recovery response thats central to slowing aging.

Rose Anne Kenny, M.D., geriatrician and author of Age Proof: The New Science of Living a Longer and Healthier Life.

I come from an Indian background where we were taught Sanskrit chanting at a very young age. It requires a lot of memorization and involves rituals and practices. We chant a lot of verses, which can be like longform poems. It seems to have a meditative effect and its a form of memory rehearsal, which can keep the brain healthy as you age. Reading complicated fiction or non-fiction books can have a similar benefit because it challenges your brain to track the characters and the plot over time.

P. Murali Doraiswamy, M.D., director of the Neurocognitive Disorders Program at Duke University School of Medicine.

I eat fruits and treat myself to an ice cream once per month. But make no mistake about itexcess sugar in all its forms is poison. It is always one of the first things I recommend eliminating for those interested in longevity. To lessen your intake of sugar, I recommend avoiding all processed foods and sugary drinks.

Sergey Young, longevity investor and author of The Science and Technology of Growing Young.

Tooth decay and gum disease are chronic infections which our immune systems can never quite get on top of. Thorough brushing and daily flossing will help prevent these, and therefore prevent chronic inflammation, one of the key drivers of aging.

Andrew Steele, Ph.D., physicist and author of Ageless: The New Science of Getting Older Without Getting Old.

Words of affirmation are crucial to my wellbeing, its important to start my day off with positivity. Each day I am also intentional about taking personal time for myself. That could be listening to an old vinyl record or simply embracing silence in an effort to calm my mind and give peace to my thoughts."

Matt Horn, Pitmaster of Horn BBQ in Oakland, CA, and author of the Horn Barbecue cookbook, out April 12.

My dad told me early on: Control what you can control and what you cant control? You cant let it bother you. One area I can just about control: raising my children, who motivate me every day. To be a better man, better dad, better human."

Trent Williams, NFL offensive tackle, cancer survivor, and subject of the new documentary, Silverback: The Trent Williams Story, out now.

I work so hard, and over time I'd developed strange guilt around resting. But there's nothing better than an hour on the couch. Everything and everyone will still be waiting for you when you get up. It's fine."

Jason Reynolds, bestselling author of more than a dozen young adult books, including his latest, Aint Burned All the Bright.

I grew up with the Gurkha and Special Forces heritage, so its all about discipline, being respectful to others, never give up on the mission you are going for, stay humble, and keep training. I always try and stay fit. That might be in the form of climbing mountains or when Im not on the mountains, I do regular work outs. One of my secrets is burpeesbut a lot of themabout 300 in one go.

Nimsdai Purja, star of the documentary 14 Peaks (Netflix), and author of Beyond Possible: One Man, Fourteen Peaks and the Mountaineering Achievement of a Lifetime.

Waiting for something wonderful can be painful if you look at it that wayWhy dont I have that promotion yet? Why cant I afford the house I want? Or it can be anticipatory joy, like waiting for Santa as a child, reveling in the hope that you will receive wonderful gifts. And when things have passed out of existence, you still get to enjoy them in the presentRemember how wonderful that vacation was? What it felt like to sail, or to ride a roller coaster? But you only can enjoy them if you are okay with the present.

Mary-Frances OConnor, Ph.D., psychology professor, director of the University of Arizonas Grief, Loss and Social Stress Lab, and author of The Grieving Brain.

Ethics is just the examination of how we make decisions that affect other people and the world we live in. By deciding to give a crap, you are acknowledging a few basic but important truths: We are not the only people who matter. We rely on others for certain things, and they rely on us. The big and small choices we make fall on a spectrum from "Excellent" to "Extremely obnoxious and bad," and where they fall is (at least in part) up to us. The only possible advice is (1) Decide to care. (2) Understand that it's a lifelong job. (3) Accept that you make progress by being a little bit better today than you were yesterday. (4) Know for a fact that from time to time, even trying your best, you're going to fail in your quest to do the right thing. And that it's okay.

Michael Schur, creator of The Good Place, co-creator of Parks and Recreation, and author of How to Be Perfect: The Correct Answer to Every Moral Question, out now.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Link:
14 Easy Ways to Extend and Enhance Your Life, Starting Now - Men's Health

Recommendation and review posted by Bethany Smith

The Steam Decks battery life isnt one of its best qualities. While this weakness is outweighed by the pleasures of playing PC games in bed or on the bus, most such games will drain the Deck quickly, requiring a degree of foresight if you want to entertain yourself on a long trip away from mains power. At the same time, different games will drain at different speeds, with some allowing Valves handheld to last hours longer than others.

Ultimately, I think the only truly accurate way to measure and judge the Steam Decks battery life is to test a bunch of different games to see how long it lasts with each. So I have! Here youll find a list of games with how long they took to empty the Decks battery from full. Ill be coming back and adding more to the list as I test them, so you can see for yourself what uptimes to expect from your favourites.

Ive also thrown in some tips on how to extend the Steam Decks battery life, which is possible even when running the thirstiest AAA games. Also, if you want to know how long a certain game will last and it isnt yet on the list, let me know in the comments it doesnt have to be one of the Steam Deck Verified games, but as long as its compatible enough to run, I may well be able to test it and add it.

Valve say the Steam Deck should last between two and eight hours, but depending on the game as well as certain hardware settings on the Deck itself battery life can vary even more. The absolute most Ive wrung out is 9h 17m (in Super Meat Boy, with Airplane mode and minimum screen brightness), while the shortest Ive seen is a scant 1h 17m (Horizon Zero Dawn with everything running at max). For this list, Ive stuck with more normal usage conditions, like setting screen brightness to 50% but leaving Wi-Fi on; you can see the full test settings on the right.

For now this is a hodgepodge of some of the most popular games on Steam by player count, and a few that I happened to have installed already, but the plan is for it to grow. Like a beautiful tall sunflower, made of numbers. Ill therefore be adding games (both new and old) on a regular basis, so again, do shout if theres one in particular youd like to see.

As rapidly as most games guzzle charge, the Steam Deck is flexible enough to give you a few different options for making that battery juice go further. In fact, almost all of these can be found in one place: the Performance tab of the Quick Settings menu. To find this, press the Quick Settings button (the three-dottted one just below the right trackpad) and select the battery icon. Lowering brightness can also help theres a slider for this in Quick Settings too, accessible via the gear icon. Here's what you can try:

Lower the display brightness A classic battery life extension trick dating back as long as adjustable backlighting has existed. Dropping the screen brightness might leave you at the mercy of reflections, especially on the 64GB and 256GB Steam Deck models (which dont have the 512GB model's matte display finish), but it can definitely help net you a few more minutes of play. Be sure to turn of dynamic brightness while youre at it, to make sure you have full control.

Limit the frame rate The Deck has a universal frame rate limiter built right in, and lowering it from 60fps to 30fps will reduce system strain to grant a modest battery life boost. I slapped a 30fps cap on Forza Horizon 5 and got 2h 03m out of it, adding an extra 26 minutes (or a 27% improvement).

Manually set the TDP limit This requires a bit of trial and error, but can prevent the Steam Deck from using more power than it needs. While in game, open the Performance tab and turn on the performance overlay so you can see your current FPS. Then, toggle the TDP limiter, set the slider all the way to the right, then lower it one step at a time until your FPS starts to drop. Slide it back up one step, and the Decks APU wont draw more power than it needs to maintain that performance level.

Manually set the GPU clock speed Similarly to the TDP limiter, you can downclock the graphics processor until its only just fast enough to deliver the performance you need and no more. Again, youre best off doing this on a per-game basis, using the FPS counter as a guide, as some games need a faster GPU than others.

Disable wireless connectivity The Decks setting menu provides am easy toggle for Airplane mode, which disables Wi-Fi and Bluetooth and thus helps stretch out battery life a little. There are also individual toggles for Wi-Fi and Bluetooth in the same place, so you can for instance shut off Wi-Fi but keep using a pair of wireless headphones.

I also tried the Decks baked-in AMD FSR upscaling, on the grounds that rendering games at a lower resolution might reduce system load and therefore power usage. It didnt really help, though: Fallout 4 with FSR emptied the battery in 1h 51m, just three minutes more than without it. Stick with the five steps above.

See original here:
The Steam Deck battery life guide: games tested and how to extend it - Rock Paper Shotgun

Recommendation and review posted by Bethany Smith

Estero Llano Grande State Park in Weslaco have been testing the use of a fungus to control an invasive species of ants attacking small animals.

The tawny crazy ants have been spreading in the Valley and the Gulf Coast. They're an invasive species from South America.

The ants have attacked small animals and even make colonies inside electric equipment, causing thousands of dollars in damage.

"There's lots of birds that when they nested, the eggs hatched, and the ants would just cover the newborn chicks," said Javier De Leon, superintendent of Estero Llano Grande State Park. "So, the newborn birds had no chance. So, we saw lots of nest failures, especially chachalacas that are born on the ground and run within minutes, just like chickens. We saw several baby chachalacas that didn't make it.

Deleon says the fungus all but eliminated the ants from the park, but warns they can also affect your home.

Look for light brown ants that don't burrow or dig like other ants.

Then, take a picture and contact the Texas A&M Agri-life Extension for help identifying them and advice on what to do.

Originally posted here:
Fungus being tested at state park in Weslaco to control invasive species of ants - KRGV

Recommendation and review posted by Bethany Smith

This practical and detailed Black Cumin Seed Oil market report provides a clear picture of trade regulation, Black Cumin Seed Oil market expansion, new product launches and innovations. It identifies Black Cumin Seed Oil market trends and future market growth in the year 2022-2029. It also introduces the Black Cumin Seed Oil market competition among the major industry players in the market. Market research analysis is a useful tool for the growth of many businesses, as this Black Cumin Seed Oil market report provides a basic knowledge of market movements and Black Cumin Seed Oil idustry trends. It tries to meet the demand for products to help central players make big profits when bringing new items to Black Cumin Seed Oil market.

Collect free Sample copy of the Black Cumin Seed Oil market report 2022: https://calibreresearch.com/report/global-black-cumin-seed-oil-market-244518#request-sample

Global Black Cumin Seed Oil Market intelligence report is a comprehensive overview of the Black Cumin Seed Oil Market position. Full information provided of past progress, current market conditions, and a future prospect is provided in the Black Cumin Seed Oil report. It also gives accurate overview of the key strategy, Black Cumin Seed Oil market size, and products of leading companies in this market segment. Complete report from Materials, Applications, and Black Cumin Seed Oil industry forecasts for 2022 are expert and in-depth research information on the global regional Black Cumin Seed Oil market situation, focusing on every region.

Henry Lamotte OILS GmbHFLAVEX Naturextrakte GmbHHenry Lamotte Oils GmbHKerfoot GroupEarthoil PlantationsLife ExtensionNuverusOmega PharmaBioPraep

Have Any Query Of Black Cumin Seed Oil Industry Report 2022: https://calibreresearch.com/report/global-black-cumin-seed-oil-market-244518#inquiry-for-buying

Food GradeCosmetic Grade

SoapHealth FoodPersonal Care Products (Massage Oils, Skin Care Products)

This Market will be significant in the Black Cumin Seed Oil growth during the forecast period. Moreover, there will be an increase in new product launches and continuous innovations due to the rise in the Black Cumin Seed Oil popularity of resulting in boosting the market in the coming years. The Black Cumin Seed Oil report provides the past, present and future Black Cumin Seed Oil industry Size, trends and the forecast information related to the expected Black Cumin Seed Oil sales revenue, growth, Black Cumin Seed Oil demand and supply scenario. Furthermore, the opportunities and the threats to the development of Black Cumin Seed Oil market forecast period from 2022 to 2029.

Get Complete Report for Better Understanding : https://calibreresearch.com/report/global-black-cumin-seed-oil-market-244518

North America Black Cumin Seed Oil Market(United States, North American country and Mexico),Europe Market(Germany, Black Cumin Seed Oil France Market, UK, Russia and Italy),Asia-Pacific market (China, Black Cumin Seed Oil Japan and Korea market, Asian nation and Southeast Asia),South America Black Cumin Seed Oil Regions inludes(Brazil, Argentina, Republic of Colombia etc.),Black Cumin Seed Oil Africa (Saudi Arabian Peninsula, UAE, Egypt, Nigeria and South Africa)

Lastly, Black Cumin Seed Oil report provides Market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. Black Cumin Seed Oil report provides critical insights on the Market dynamics and will enable strategic decision making for the existing Market players as well as those willing to enter the Black Cumin Seed Oil Market .

Read more:
Industry Inspection Overview of Black Cumin Seed Oil Machine Market 2022-29 | Earthoil Plantations, Life Extension, Nuverus, Omega Pharma FortBendNow...

Recommendation and review posted by Bethany Smith

Marine leaders have been pushing since for the first light amphibious warship to be procured by 2023.

But in the services recent combined budget request with the Navy, the Corps isnt expecting to get the ship for at least another two years. And the Corps only is likely to get four of them in inventory by 2027 if the current plan holds.

The light amphibious warship is the Corps answer to moving a lot of Marines in small teams from deep water to the close-to-shore littoral zones and even conducting beach landings.

Far cheaper than the larger amphibious ships that Marines usually take to combat, the light amphibious warship is expected to fill a gap between big-deck ships and small landing craft. Without it, Marines face serious obstacles in getting on land. Thats critical as the Corps has billed itself as the Navys ship-killing, adversary-harassing force.

Each light amphibious warship is expected to carry up to 75 Marines. The Corps wants to use a host of them to move its newest formation creation, the Marine littoral regiment, around the littoral battlespace.

Thats going to be hard when even by 2027 it will only have enough space aboard potentially four new vessels for fewer than three reduced-strength, unsupported infantry companies.

To meet Marine war planning expectations, theyll likely eventually need enough light amphibious warships to transport at least three Marine littoral regiments.

But the Marine Corps will have to wait at least until fiscal year 2025, according to the militarys proposed fiscal year 2023 budget released on Monday. The Navy expects to start funding builds of the light amphibious warship with one in 2025, another in 2026 and two in 2027.

Marine Corps Commandant Gen. David Berger said at the National Defense Industrial Associations annual Expeditionary Warfare Conference in February that the traditional amphib ships and the new light amphibious warship concept complement each other. They will work in tandem to bring Marines to the fight.

More details on budget specifics will be available in the coming weeks. But the Pentagons initial budget request gives glimpses as to what will happen with Marines and ships in the near- to mid-term.

At a briefing with media on Monday, Navy Rear Adm. John Gumbleton, deputy assistant secretary of the Navy for budget, said that both the Navy and Marine Corps were working to get the requirements tight for the light amphibious warship.

He pointed to funding in research and development rather than procurement in the near term.

While still in the design phase, the Marines are asking to build a 200- to 400-foot ship with a maximum draft of 12 feet. The ship must be able to carry between 3,000 and 4,000 tons and 75 Marines with a Navy crew of about 40 sailors.

That program saw $20 million in funding in fiscal 2021, $13 million in fiscal 2022 and hovers around $12 million for the pending 2023 budget.

Thats behind the timeline in the Corps goal of having a light amphibious warship funded by 2023 and deployable soon after.

The Navys $27.9 billion shipbuilding proposal expects to fund nine new ship builds. More than half of that money is taken up by incremental funding for the Ford-class aircraft carrier, the Columbia-class and the Virginia-class nuclear submarines.

Of what remains in the purse, a handful of Marine-focused priorities look to get funding, though not at quite at the level or pace Corps leadership has pushed for in recent years.

Two of those the America class amphibious assault ship-LHA 6 and the San Antonio class amphibious transport dock or LPD 17 Flight II are on deck for funding.

In existing construction or serve life extension, the Navy looks to pay for two landing craft air cushion and two ship-to-shore connectors in 2023, also key to Marine gear and troop movement in the littorals.

The Marines F-35C Joint Strike Fighter purchases dropped to nine for the 2023 budget, but would resume at 15 each year until fiscal 2027. The Corps purchased 16 in fiscal 2021 and 15 in fiscal 2022.

Purchases of the F-35B are consistent with 15 planned in the fiscal 2023 budget and 16 each year until 2026, with 17 in fiscal 2027. In the 2022 budget, Marines bought 17 of the B variant, having purchased 10 in fiscal 2021.

Both Navy and Marine Corps aviators are getting a new trainer, the Corps will see four such aircraft in this 2023 budget and 22 total over the next two years.

KC-130J buys are steady at five and another two planned for fiscal 2024. The Corps bought 11 over the previous two fiscal years.

Marine aviators are likely to see many more CH-53K King Stallion helicopters in the coming years.

The proposal lays out a plan to buy 10, with another 78 spread out over the next four years.

Research and development spending on the King Stallion continues, though lower than in years past. Current figures in the budget call for $220 million, down from $257 million in fiscal 2022.

It appears the Marines are done buying MV-22 Ospreys for the foreseeable future.

Two years ago, the Corps purchased three, and in 2022, it was given funding for nine. But no future purchases are planned within this budget through fiscal 2027.

Todd South has written about crime, courts, government and the military for multiple publications since 2004 and was named a 2014 Pulitzer finalist for a co-written project on witness intimidation. Todd is a Marine veteran of the Iraq War.

Read the original:
Marines will have to wait at least until 2025 for light amphibious warship - Marine Corps Times

Recommendation and review posted by Bethany Smith